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Cancer
Abstract
The nuclear receptor (NR) superfamily represents a structurally-conserved group of ligand-regulated
transcription factors. These proteins have critical roles in various physiological and pathological
processes, including cancer, and have been targets of drug therapy. The orphan NR subfamily 4A (NR4A),
which includes the NR4A1 (Nur77), NR4A2 (Nurr1), and NR4A3 (Nor-1) genes, has been implicated in
adult solid tumors and has been characterized as pro-tumorigenic mediator of cell proliferation,
transformation, migration, and drug resistance. Alternatively, in leukemia, NR4A1 and NR4A3 have been
described as tumor suppressors in hematologic malignancies. Members of the NR4A family are
commonly overexpressed in cancer and this has been attributed to their regulation by other oncogenic
signaling pathways.
Despite the understanding of signaling cascades that lead to overexpression of the NR4A members, little
is known about their regulation by microRNAs (miRNAs). miRNAs are small, non-coding, endogenous
RNAs that are transcribed, processed, and used to direct cellular proteins that destabilize or block
translation of target mRNA. In this study, we first sought to determine the miRNAs that are responsible for
regulating NR4A2. Using a 3ʹ UTR reporter assay, we identified miR-34 as a regulator of the NR4A2
through its 3ʹ UTR, which was confirmed using mutagenesis of the predicted binding region of the miR-34
seed region to its target site. We demonstrated that overexpression of exogenous or induction of
endogenous miR-34 expression downstream of p53 activation by Nutlin-3a was associated with
decreased endogenous NR4A2. Additionally, overexpression of NR4A2 was capable of suppressing the
activation of p53 target genes, and was also able to attenuate the sensitivity of cells to the antiproliferative effect of Nutlin-3a.
We further explored the roles of the NR4A family in pediatric cancer, an area that has not been fully
investigated. We first determined that the members of the NR4A family are overexpressed in
rhabdomyosarcoma (RMS) cell lines compared to normal muscle cells. Knockdown of NR4A1 or NR4A2
led to a reduction in cell proliferation and transformation, while knockdown of NR4A2 could also affect
cell migration. Using a microarray approach, we sought to investigate the transcriptome-level changes in
response to NR4A knockdown, and determined that knockdown of NR4A2 led to a unique gene signature,
while NR4A1 and NR4A3 knockdown had large overlaps in expression changes. These unique gene
expression changes in response to NR4A2 knockdown could explain the unique effects that NR4A2 has
on migration.
Overall, this study has discovered miR-34 as a novel regulator of NR4A2, and places NR4A2 in a potential
feedback mechanism involving p53, miR-34, and NR4A2. This could indicate that NR4A2 mediates at
least some of its pro-oncogenic effects through the inhibition of p53, which is relieved by p53 itself upon
activation. Alternatively, NR4A2, is shown to have other roles in cancer progression, potentially through
novel downstream target genes. These data may be used in understanding the effects of miR-34
replacement therapy, as this method of treatment is progressing through clinical trials, allowing us to
understand the diverse regulator cascades being modulated.
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ABSTRACT
The nuclear receptor (NR) superfamily represents a structurally-conserved group
of ligand-regulated transcription factors. These proteins have critical roles in various
physiological and pathological processes, including cancer, and have been targets of drug
therapy. The orphan NR subfamily 4A (NR4A), which includes the NR4A1 (Nur77),
NR4A2 (Nurr1), and NR4A3 (Nor-1) genes has been implicated in adult solid tumors and
have been characterized as pro-tumorigenic mediator of cell proliferation, transformation,
migration, and drug resistance. Alternatively, in leukemia, NR4A1 and NR4A3 have been
described as tumor suppressors in hematologic malignancies. Members of the NR4A
family are commonly overexpressed in cancer and this has been attributed to their
regulation by other oncogenic signaling pathways.
Despite the understanding of signaling cascades that lead to overexpression of the
NR4A members, little is known about their regulation by microRNAs (miRNAs).
miRNAs are small, non-coding, endogenous RNAs that are transcribed, processed, and
used to direct cellular proteins that destabilize or block translation of target mRNA. In
this study, we first sought to determine the miRNAs that are responsible for regulating
NR4A2. Using a 3ʹ UTR reporter assay, we identified miR-34 as a regulator of the NR4A2
through its 3ʹ UTR, which was confirmed using mutagenesis of the predicted binding
region of the miR-34 seed region to its target site. We demonstrated that overexpression
of exogenous or induction of endogenous miR-34 expression downstream of p53
activation by Nutlin-3a was associated with decreased endogenous NR4A2. Additionally,
overexpression of NR4A2 was capable of suppressing the activation of p53 target genes,
and was also able to attenuate the sensitivity of cells to the anti-proliferative effect of
Nutlin-3a.
We further explored the roles of the NR4A family in pediatric cancer, an area that
has not been fully investigated. We first determined that the members of the NR4A
family are overexpressed in rhabdomyosarcoma (RMS) cell lines compared to normal
muscle cells. Knockdown of NR4A1 or NR4A2 led to a reduction in cell proliferation and
transformation, while knockdown of NR4A2 could also affect cell migration. Using a
microarray approach, we sought to investigate the transcriptome-level changes in
response to NR4A knockdown, and determined that knockdown of NR4A2 led to a
unique gene signature, while NR4A1 and NR4A3 knockdown had large overlaps in
expression changes. These unique gene expression changes in response to NR4A2
knockdown could explain the unique effects that NR4A2 has on migration.
Overall, this study has discovered miR-34 as a novel regulator of NR4A2, and
places NR4A2 in a potential feedback mechanism involving p53, miR-34, and NR4A2.
This could indicate that NR4A2 mediates at least some of its pro-oncogenic effects
through the inhibition of p53, which is relieved by p53 itself upon activation.
Alternatively, NR4A2, is shown to have other roles in cancer, potentially through novel
downstream target genes. These data may be used in understanding the effects of miR-34
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replacement therapy, as this method of treatment is progressing through clinical trials,
allowing us to understand the diverse regulator cascades being modulated.

vi

TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION .....................................................................................1
Nuclear Receptors ............................................................................................................1
Discovery of the nuclear receptor superfamily ............................................................1
Domain structure and function.....................................................................................1
N-terminal domain and AF-1 .................................................................................. 1
DNA-binding domain ............................................................................................. 3
Ligand-binding domain and AF-2 .......................................................................... 3
Nuclear receptors and cancer .......................................................................................3
Glucocorticoid receptor .......................................................................................... 3
Estrogen receptor .................................................................................................... 4
Androgen receptor .................................................................................................. 5
Orphan nuclear receptors ........................................................................................ 5
microRNAs ......................................................................................................................6
microRNA biogenesis and function .............................................................................6
miRNAs and cancer .....................................................................................................6
Tumor-suppressor–like miRNAs ............................................................................ 9
OncomiRs ............................................................................................................... 9
Hypothesis and Specific Aims .........................................................................................9
CHAPTER 2. THE INTERPLAY OF NR4A RECEPTORS AND THE
ONCOGENE–TUMOR SUPPRESSOR NETWORKS IN CANCER ........................11
Introduction ....................................................................................................................11
NR4A Receptors in Cancer............................................................................................11
NR4A Receptors and MAPK .........................................................................................14
MAPK and cancer ......................................................................................................14
Regulation of NR4A receptors by MAPK .................................................................15
NR4A Receptors, PI3K-AKT, and mTOR in Proliferation and Survival .....................16
PI3K-AKT and cancer ...............................................................................................16
The interplay of NR4A receptors and PI3K-AKT .....................................................16
The interplay of NR4A receptors and mTOR ............................................................17
NR4A Receptors, Hypoxia, and Angiogenesis ..............................................................18
HIF-1 and cancer ........................................................................................................18
The interplay of NR4A receptors and HIF-1 .............................................................19
NR4A receptors as mediators of VEGF-induced angiogenesis .................................20
NR4A Receptors, p53, and Cell Death ..........................................................................21
p53 and cancer ...........................................................................................................21
The interplay of NR4A receptors and p53 .................................................................22
Nur77 in cell death .....................................................................................................23
NR4A, Wnt, and β-catenin ............................................................................................27
Wnt and cancer...........................................................................................................27
The interplay of NR4A receptors and Wnt signaling ................................................27
CHD1L Oncogene and Nur77 .......................................................................................28
CHD1L and cancer ....................................................................................................28
vii

The interplay of Nur77 and CHD1L ..........................................................................29
Concluding Remarks......................................................................................................30
CHAPTER 3. THE ORPHAN NUCLEAR RECEPTOR NR4A2 IS PART OF A
P53–MICRORNA-34 NETWORK.................................................................................33
Introduction ....................................................................................................................33
Results ............................................................................................................................34
Identification of miRNAs directly targeting the 3ʹ UTR of NR4A2 ..........................34
miR-34 regulates endogenous NR4A2 levels .............................................................37
p53 activation suppresses endogenous NR4A2 levels ................................................39
Overexpression of NR4A2 suppresses p53 activation ................................................41
Knockdown of NR4A2 enhances p53 activation ........................................................41
Overexpression of NR4A2 attenuates Nutlin-3a sensitivity .......................................44
Discussion ......................................................................................................................44
Materials and Methods...................................................................................................49
Cell culture .................................................................................................................49
3ʹ UTR reporter plasmid and microRNA screen ........................................................50
miRNA target prediction and mutagenesis ................................................................50
Molecular cloning ......................................................................................................50
miRNA mimics, RNAi, and chemical treatments ......................................................50
RNA extraction and quantitative real-time PCR .......................................................51
Protein extraction and Western blot analysis .............................................................51
Chromatin immunoprecipitation (ChIP) ....................................................................52
Cell viability assays ...................................................................................................52
Analyses of expression data from online databases ...................................................52
Statistical analyses .....................................................................................................53
CHAPTER 4. INVESTIGATING THE EXPRESSION AND FUNCTION OF
NR4A NUCLEAR RECEPTORS IN RHABDOMYOSARCOMA ............................54
Introduction ....................................................................................................................54
Results and Discussion ..................................................................................................55
NR4A nuclear receptors are overexpressed in RMS .................................................55
Knockdown of NR4A1 and NR4A2 decreases cell proliferation ................................55
Knockdown of NR4A2 decreases cell migration........................................................58
Knockdown of NR4A1 and NR4A2 decreases colony formation ...............................58
NR4A2 knockdown leads to an altered transcriptional profile ...................................62
Conclusions ....................................................................................................................62
Materials and Methods...................................................................................................65
Cell culture .................................................................................................................65
Transfection of siRNA, RNA extraction, and quantitative real-time PCR ................65
Cell proliferation and cell cycle assays ......................................................................65
Cell migration assays .................................................................................................66
Colony formation assay .............................................................................................66
DNA microarray ........................................................................................................66

viii

CHAPTER 5. DISCUSSION ..........................................................................................68
NR4A Regulation by miRNAs in Cancer ......................................................................68
NR4A Function in Cancer .............................................................................................70
NR4A2 and p53 suppression .....................................................................................70
NR4A receptors in rhabdomyosarcoma .....................................................................71
LIST OF REFERENCES ................................................................................................72
APPENDIX. SUPPLEMENTAL DATA FOR CHAPTER 3 ......................................88
VITA................................................................................................................................102

ix

LIST OF TABLES
Table 2-1.

Summary of gene expression changes after treatment with NR4A
agonists or antagonists. ................................................................................24

Table 3-1.

MicroRNAs that putatively regulate NR4A2 through its 3ʹ UTR. ................36

Table A-1.

List of miRNAs screened. ............................................................................89

Table A-2. List of primers used. ...................................................................................100

x

LIST OF FIGURES
Figure 1-1. The nuclear receptor signaling pathway. ........................................................2
Figure 1-2. The microRNA biogenesis pathway. ..............................................................7
Figure 1-3. Dysregulation of miRNAs can contribute to cancer. ......................................8
Figure 2-1. Nur77 mediates cell death or survival through localization-dependent
and –independent mechanisms. ....................................................................13
Figure 2-2. The NR4A family and key signaling pathways regulate each other. ............31
Figure 3-1. Screening for miRNAs that directly target the 3′ UTR of NR4A2. ...............35
Figure 3-2. miRNA-34 downregulates endogenous NR4A2. ..........................................38
Figure 3-3. Nutlin-3a activation of p53 decreases endogenous NR4A2. ........................40
Figure 3-4. NR4A2 overexpression suppresses p53 activation. .......................................42
Figure 3-5. Knockdown of NR4A2 enhances p53 activation. ..........................................43
Figure 3-6. Overexpression of NR4A2 attenuates Nutlin-3a sensitivity. .........................45
Figure 3-7. Graphical summary. ......................................................................................46
Figure 4-1. NR4A nuclear receptors are overexpressed in rhabdomyosarcoma cell
lines. .............................................................................................................56
Figure 4-2. Knockdown of NR4A1 and NR4A2 decreases cell proliferation. ..................57
Figure 4-3. Knockdown of NR4A2 decreases cell migration. .........................................59
Figure 4-4. Knockdown of NR4A1 and NR4A2 decreases colony formation. .................61
Figure 4-5. Gene expression following NR4A knockdown. ...........................................63
Figure A-1. Correlation of miR-34a and NR4A2 expression in rectum
adenocarcinoma patients. .............................................................................91
Figure A-2. miR-34a correlation matrix in rectum adenocarcinoma patients. .................93
Figure A-3. Overexpression of miR-34 increases p53 protein and acetylation levels. ....95
Figure A-4. Overexpression of miR-34 decreases NR4A2 in RKO colorectal cancer
cells. .............................................................................................................96

xi

Figure A-5. Nutlin-3a enhances p53 and p21 protein levels in RKO and SW48
colorectal cancer cell lines. ..........................................................................97
Figure A-6. p53 activation by Nutlin-3a decreases NR4A2 in RKO and SW48 cell
lines. .............................................................................................................98
Figure A-7. Overexpression of NR4A2 does not affect binding of p53 to target gene
promoters. .....................................................................................................99
Figure A-8. Validation of an anti-NR4A2 antibody. ......................................................101

xii

CHAPTER 1.

INTRODUCTION

Nuclear Receptors
Discovery of the nuclear receptor superfamily
Three decades ago, the glucocorticoid (GR) and estrogen (ER) receptors were the
first described nuclear receptors (NRs) [1-4], and since then much has been discovered in
regard to this group of key transcriptional regulators in physiological and pathological
events. Following characterization of GR and ER, additional proteins which shared
conserved domains began to be discovered [5], and now the human NR superfamily
consists of 48 genes that encode a highly homologous set of transcription factors. This
superfamily of proteins shares similar structural organization, composed of modular
domains [6, 7] that include (listed from N- to C-terminal) an N-terminal domain which
harbors an activation function-1 (AF-1) region, a DNA-binding domain (DBD), a flexible
hinge region, and a C-terminal ligand-binding domain (LBD) that contains an AF-2
region.
These mostly ligand-regulated transcription factors control target gene expression
through mechanisms typically involving ligand binding, dimerization, nuclear
localization, and recruitment and association with coregulators at sites in gene promoters
(Figure 1-1). Upon initial cloning of the various NR members, those lacking a defined
ligand were termed ‘orphan’ receptors—some of which have remained ‘orphans,’ while
others have been ‘adopted’ following identification of their cognate ligand. Those with
known ligands typically are activated by steroid or thyroid hormones, vitamins, fatty
acids, bile acids, sterols, or xenobiotics [8]. Several key members of the NR family have
been utilized as drug targets [9, 10], and it was reported that 13% of FDA-approved drugs
were NR modulators, representing the second-leading class of drug targets at that time
[11]. Additionally, other NRs, such as PXR and CAR, have been studied for their roles in
regulating transcriptional target genes that are involved in drug metabolism, having
implications in drug–drug interactions and drug toxicity [12, 13].
Domain structure and function
N-terminal domain and AF-1
The N-terminal domain of NRs is divergent among the different NR subfamilies
and isoforms, with large variability in the size of this domain. Encoded in the N-terminal
domain is the AF-1 region, which can function independently of ligand binding [14]. This
region is also important in post-translational regulation of NR function through
phosphorylation or protein-protein interactions [15-18]. These regulatory mechanisms
can serve to affect the protein levels or transcriptional activity of the NR.
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Figure 1-1. The nuclear receptor signaling pathway.
The nuclear receptor (NR) signaling cascade begins with an endogenous or synthetic
ligand for a specific NR enters the cell and binds to the ligand-binding domain (LBD) of
the NR. This triggers a dimerization of either homo- or hetero- NR binding partners. This
binding causes an exposure of a nuclear localization signal, at which time the dimer is
translocated to the nucleus where it recruits coactivators and the transcriptional
machinery. This complex directs the transcription of NR target genes through its DNAbinding domain (DBD) depending on specific recognition elements in the DNA. The
resultant gene is transcribed into protein and subsequently mediates the biological
response of NR activation.

2

DNA-binding domain
The DBD is the most conserved region among the members of the NR
superfamily. This region contains two zinc finger motifs, which direct the DNA-binding
activities of each NR to double stranded DNA at receptor-specific response elements
[19]. These DNA response elements have specific sequences to confer the NR-specific
binding activities for the regulation of corresponding target genes. The DBD also
contains a nuclear localization signal (NLS) which, when exposed, directs NR complexes
to the nucleus upon ligand binding [20].
Ligand-binding domain and AF-2
The LBD is the second most conserved region among NRs, and is the domain that
makes NRs unique from other transcription factors. The LBD is responsible for binding
endogenous or synthetic ligands to activate downstream NR signaling. This domain also
contains the AF-2 region, which directs ligand-dependent recruitment of coregulators
[14]. The LBD encodes the major interface for NR dimerization upon ligand binding
[21]. Using sequence-based and crystallographic studies, it was determined that NRs
share common folding in the LBD region [22], which consists of a series of α-helices,
referred to as H1H12. These helices form the pocket in which the ligand binds. Binding
of ligand causes a shift of the helices with H12 closing the cavity for a more stable holoconformation [23]. H12 encodes part of the AF-2 which, when closed in the holo-form,
presents a hydrophobic cleft for the coactivator recruitment.
Nuclear receptors and cancer
In addition to NRs having important roles in normal physiological contexts, NR
dysregulation can occur and lead to various disease states including cancer. Examples of
this include several hormone-dependent cancers, such as breast and prostate cancer,
where NRs play a critical role in the development, progression, and resistance of these
malignancies to therapy. As a result, these NRs have been targeted by small molecule
modulators and hormone therapy as a way to treat disease.
Glucocorticoid receptor
The glucocorticoid receptor (GR) serves as the receptor for natural (cortisol) and
synthetic (dexamethasone, prednisone/prednisolone, and budesonide) glucocorticoids
(GCs). As the physiological function of GCs are to minimize inflammation, these steroid
molecules were first used therapeutically for the treatment of rheumatoid arthritis [24].
Synthetic GCs are commonly prescribed for various diseases with inflammatory
conditions, including asthma and dermatitis [25]. GCs have also been used in the
treatment of lymphoid malignancies, including acute lymphoblastic leukemia (ALL) [26].
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The therapeutic response to GCs in ALL can be attributed primarily to the
transcriptional activity of GR and is dependent on GC binding to GR [27]. Binding of GC
to GR leads to cytoplasmic-to-nuclear translocation of GR, where it can then bind to
target gene promoters and cause transactivation or repression of gene expression. Some
of the GC-mediated effects include inhibition of cell proliferation and induction of
apoptosis. Genes induced by GCs include Bim, Bid, and Bad, which promote apoptosis,
while genes involved in inhibition of apoptosis (Bcl-2, Mcl-1, and Bcl-xL) are suppressed
by GCs [27], leading to a GC-mediated apoptosis during therapy. Resistance to GCs can
occur through various methods, including low GR expression in cells [28], mutations in
GR [29, 30], or other alterations that affect GR directly such as overexpression of CASP1
[31].
Estrogen receptor
The estrogen receptor alpha (ERα) and beta (ERβ) are receptors for endogenous
estrogens, which includes estrone (E1), 17β-estradiol (E2), and estriol (E3). Estrogen is
important in normal physiology, and is normally secreted by the ovaries in
premenopausal women. High levels of estrogen have been associated with cancer in
various tissues of both women and men, although the understanding of estrogens in
cancer progression is understood predominantly from studies in breast and endometrial
cancers [32]. The ability for estrogen to promote cancer development and progression is
mediated mostly through ERα-mediated transcriptional activation of target genes which
include c-Myc [33] and cyclin D1 [34] to promote cell proliferation, and Bcl-2 [35] to
block the apoptotic response and promote cell survival. As a normal physiological
response of promoting new blood vessel formation (angiogenesis) in the uterus, estrogen
can also induce genes responsible for this process in breast cancer cells [36], which is a
critical component of tumor progression, allowing new blood flow to developing tumor.
Although ER expression appears important for primary tumor formation, the loss of ER
expression portends a more aggressive, invasive, and deadly disease [37] with a high
propensity to metastasize, at which time targeting ER is no longer feasible.
Targeting of ERα with small molecule modulators has been a focus, and
somewhat effective, strategy of treating hormone-dependent cancers. Tamoxifen,
developed as the first selective estrogen receptor modulator (SERM), is able to reduce
breast cancer recurrence and mortality, and is used as the front line drug for ER-positive
breast cancers. SERMs are small molecules that are able to mimic estrogen and bind to
the ER LBD, but rather act as an antagonist of ER function by blocking endogenous
estrogen signaling through this axis [38]. Development of resistance is a major problem
of tamoxifen and other therapies for breast cancer patients. Cytochrome P450 enzyme
CYP2D6 is the primary metabolizer of tamoxifen into its active metabolite and, as a
means of resistance, CYP2D6 polymorphisms leads to lower clinical efficacy [39].
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Androgen receptor
The androgen receptor (AR) serves as the ligand for endogenous testosterone and
its more active metabolite form, 5α-dihydrotestosterone. These androgens are formed in
the testes by Leydig cells, and serve to regulate gene expression that primarily directs
male sexual development. Androgens and AR also stimulate proliferative and survival
pathways in prostate cells, and the dysregulation of these actions leads to development of
prostate cancer [40]. A common test to indicate the need for patient surveillance or
biopsy is measurement of serum levels of prostate-specific antigen (PSA), a wellcharacterized target gene of AR [41], which indicates increased androgen signaling.
Studies have shown that 159 different mutations in AR itself can predispose men to
develop prostate cancer [42].
Classically, removal of the testes was found to cause prostate cancer regression
through the deprivation of androgen stimulation. Synthetic, non-steroidal antiandrogens
have been developed that are capable of blocking androgen signaling, and these include
flutamide, bicalutamide, and nilutamide [40]. Although structural studies have not
confirmed their mechanism of action, it is believed that these antiandrogens bind to the
LBD of AR, competing out the endogenous androgen binding. Resistance to androgen
deprivation and blockade can develop, at which point the disease becomes deadly and
difficult to treat, and is referred to as castration-resistant prostate cancer (CRPC) [43].
Several mechanisms of CRPC have been described, including increased AR expression
and mutations in AR which cause it to either become activated by other endogenous
steroids as a means to bypass the need for androgens or insensitive to the actions of
antiandrogens.
Orphan nuclear receptors
Those NRs which have no identified endogenous ligands are classified as orphan
NRs. This subset of receptors affect a multitude of physiological responses. Due to the
absence of identified ligands, studies suggest that these NRs can act independently of
ligand through constitutive activation, influenced through post-translational modifications
or protein-protein interactions. Much like their ligand-associated family members, the
orphan NRs can positively or negatively regulate gene expression through their DBD
region.
Additionally, the actions of orphan NRs have been linked to cancer development
and progression [44], which includes the known functions of one orphan NR subfamily,
the NR4A receptors. The NR4A family, which includes NR4A1 (Nur77), NR4A2
(Nurr1), and NR4A3 (Nor-1), has been demonstrated to primarily have oncogenic roles in
many adult solid tumors as a result of oncogene and tumor suppressor signaling in cancer
[45]. NR4A1 and NR4A3 have also been shown to be downregulated and act as tumor
suppressors in leukemia, with deletion of these NRs leading to rapid acute myeloid
leukemia (AML) in mice [46]. Research primarily led by Safe and colleagues has
targeted the NR4A receptors, primarily NR4A1, through the development of small
molecule methyl-substituted diindolylmethanes (C-DIM) as inhibitors of
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NR4Amoncogenic activity [47-49]. Alternatively, some C-DIMs and another compound,
cytosporone B, can activate proapoptotic functions of NR4A1 [49-55]. Another route of
NR4A targeting has included altering the subcellular localization of NR4A1 to promote
mitochondrial-associated apoptosis [56] or through the targeting of NR4A1 interactions
with other proteins [57-59].
microRNAs
microRNA biogenesis and function
microRNAs (miRNAs) are small, endogenous, non-coding RNAs of
approximately 22 nucleotides in length. Genes encoding miRNAs are transcribed from
DNA by RNA polymerase II (Pol II) [60]. miRNA genes can be encoded in introns or
exons of non-coding or protein-coding regions, and can exist alone or as a polycistronic
transcript of multiple miRNAs. Transcription by Pol II forms a primary miRNA (primiRNA), which is then processed by the RNase Drosha to form a precursor miRNA (premiRNA) [61]. The pre-miRNA is exported from the nucleus by Exportin 5 into the
cytoplasm [62]. Further processing occurs in the cytoplasm by the RNase Dicer, cleaving
it into a small RNA duplex [63]. This short RNA duplex is loaded into a preRNAiinduced silencing complex (RISC), which contains an Argonaute (AGO) protein [64].
The pre-RISC is responsible for unwinding the miRNA duplex, retaining only the active
strand.
Upon formation of the mature miRNA-containing RISC, this active complex is then
directed primarily to 3′ untranslated regions (UTR) in target mRNAs, acting as a guide to
direct gene or protein suppression [65]. The miRNA recognizes its targets based on
nucleotide complementarity within the 3ʹ UTR, and partial pairing of the mature miRNA
with the 3ʹ UTR can be sufficient for target recognition [66]. The critical nucleotides for
miRNA-mediated suppression are in positions 2–7 at the 5ʹ end of the miRNA, which is
referred to as the seed region of the miRNA [67]. The RISC then directs mRNA
degradation, destabilization, or translational repression of target mRNAs [65], resulting
in miRNA-mediated suppression of protein expression (Figure 1-2) and ultimately
reduced protein function and biological activity.
miRNAs and cancer
Dysregulation of miRNAs has been attributed to the development and progression
of cancer [68]. This is accomplished depending on the particular genes that a miRNA is
responsible for targeting, with an alteration in the expression of the miRNA causing a
resultant change in its target genes. Much like protein-coding genes that are involved in
cancer, miRNAs can be classified as either oncomiRs or tumor-suppressorlike miRNAs
(Figure 1-3).
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Figure 1-2. The microRNA biogenesis pathway.
MicroRNAs (miRNAs) are first transcribed from genes encoding each respective miRNA
by RNA polymerase II (Pol II). The resulting transcript is referred to as pri-miRNA, and
can exist as a single miRNA (monocistronic) or as a miRNA cluster (polycistronic). The
pri-miRNA is then processed by the RNAase Drosha to form the pre-miRNA form. The
pre-miRNA is then exported from the nucleus into the cytosol by Exportin-5, where it
becomes further processed by the RNase Dicer. The duplex miRNA now incorporates
into an Argonaute (Ago2)-containing RNAi-induced silencing complex, where the duplex
unwinds and the unstable star-strand (miR*) becomes degraded. Using the loaded active
miRNA strand as a guide, the RISC binds to the 3ʹ UTR of miRNA target genes, leading
to mRNA transcript degradation or inhibition of ribosomal translation of mRNA into
protein.
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Figure 1-3. Dysregulation of miRNAs can contribute to cancer.
MiRNAs are able to act as tumor suppressors or oncogenes (referred to as oncomiRs)
depending on the target genes that they suppress. Tumor-suppressor like miRNAs are
described as targeting a gene that normally acts as an oncogene, but when this miRNA
has reduced or absent expression, the oncogene is no longer suppressed and can increase
in expression to promote cancer phenotypes. An oncomiR is a miRNA that targets a
tumor suppressor, and the aberrant overexpression of this miRNA leads to decreased
tumor suppressor expression and function, resulting in unchecked tumorigenesis. Cancerrelated miRNAs have been shown to contribute to multiple steps of cancer development,
progression and metastasis, and therapeutic resistance.
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Tumor-suppressor–like miRNAs
Tumor-suppressor-like miRNAs are those miRNAs that typically are responsible
for regulating genes that promote cell proliferation, survival, or other tumor-promoting
processes. As are tumor suppressor proteins, the expression of tumor-suppressorlike
miRNAs are decreased or lost due to factors such as loss in transcription factor
regulation, epigenetic silencing, or genomic deletion [69]. This loss in miRNA expression
allows the resulting target gene to become increased in expression, contributing to factors
that promote cancer at multiple steps of oncogenesis.
One example of a tumor-suppressorlike miRNA is the miR-34 family. This
family of miRNAs consists of three isoforms (miR-34a/b/c) that share a common seed
region. The miR-34a family is transcriptionally regulated by the tumor suppressor protein
p53 [70, 71], and has been attributed to partially carrying out tumor suppressive functions
of the p53 response. As such, loss of p53 activity through deletion or mutation could be
attributed to a decrease in miR-34 expression. Additionally, miR-34 expression can be
lost through epigenetic silencing [72] or through deletions, as in the case of
neuroblastoma [73, 74]. Genes that are regulated by miR-34 include those involved in
cell cycle progression, antiapoptotic and survival responses, and migration and metastasis
[75].
OncomiRs
Alternatively, miRNAs can act similar to oncogenes. These miRNAs are termed
oncomiRs, and are responsible for regulating genes that normally have tumor suppressive
function. OncomiRs become increased in expression, typically by increased transcription
factor signaling at the transcriptional level [68]. One example of an oncomiR includes
miR-21, which was the first described oncomiR [76]. miR-21 regulates genes such as
PTEN [77] and other tumor suppressor genes to elicit it’s cancer-promoting effects, and it
is found to be overexpressed in many tumor types.
Hypothesis and Specific Aims
Research by other groups suggests that overexpression of NR4A1 and NR4A2
could promote cell proliferation, migration, transformation, and survival in cancer.
Understanding how members of the NR4A subfamily are regulated and determining their
roles in cancer is the first step in understanding their biological relevance and usefulness
as therapeutic targets. Although much is known about the cell signaling events that
regulate NR4A expression, very little is known regarding the contributions of miRNAs in
regulating this NR subfamily. Additionally, the function of NR4A NRs in pediatric
malignancies has not been investigated.
We hypothesize that due to the previously described overexpression of NR4A
family members in solid tumors, particularly NR4A1 and NR4A2, that regulation of the
NR4A members by tumor-suppressor–like miRNAs is a contributing factor to their
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overexpression, and that in turn, NR4A family members contribute to cancer phenotypes
through their control of gene expression. To test this hypothesis, we carried out the
following specific aims:
1. Investigate the regulation of NR4A2 by miRNAs and characterize the relevance
of this regulatory mechanism in cancer.
2. Determine the roles of the NR4A receptors in caner and examine the gene
expression changes as a result of NR4A modulation.
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CHAPTER 2. THE INTERPLAY OF NR4A RECEPTORS AND THE
ONCOGENE–TUMOR SUPPRESSOR NETWORKS IN CANCER*
Introduction
The human nuclear receptor (NR) family is a group of structurally related
transcription factors that regulate specific gene expression in a ligand-dependent manner.
This superfamily of receptors constitutes an important group of drug targets that are
useful in identifying compounds that affect a wide range of physiological and
pathological events [9]. NRs share a common structural arrangement that consists of an
N-terminal domain containing an activation function–1 (AF-1) region, a DNA-binding
domain, a hinge region, and a C-terminal ligand-binding domain (LBD) that can also
encode an AF-2 domain. NR subfamily 4 group A (NR4A) is composed of three
members: Nur77 (NR4A1, also known as nerve growth factor IB or NGFIB), Nurr1
(NR4A2), and Nor-1 (NR4A3).
Members of the NR4A subgroup respond to various stimuli, and their expression
can be induced by mitogens, stress, and apoptotic signals, implicating their roles in
multiple biological processes [78, 79]. The NR4A receptors are classified as orphan
receptors, having no known physiological ligands, and do not contain a typical ligandbinding domain structure common to other NRs [78, 80-82] although recent evidence
suggests that unsaturated fatty acid metabolites could serve as the missing ligand for
Nur77 [83]. Typical NRs have a ligand-binding domain containing a hydrophobic cleft
for ligand- and coactivator-binding, but structural studies show that the NR4A subgroup
contains an atypical ligand-binding groove that is hindered by bulky side groups of
hydrophobic residues. Thus, the NR4A receptors are believed to be regulated in a ligandindependent manner, and a growing amount of literature supports the notion that these
receptors are regulated largely by post-translational modifications and protein-protein
interactions and that their expression and localization within the cell influences their
cellular functions.
NR4A Receptors in Cancer
The NR4A receptors promote or suppress tumors depending on specific cellular
context. For example, Nur77 is overexpressed in cancer cell and tissue samples of
multiple origins, causing increased proliferation and survival in these cells and tissues
[84] at least partly via upregulation of several target genes, including cyclin D2 [16],
E2F1 [85], survivin [47], and thioredoxin domain–containing 5 (TXNDC5) [48], which
-------------------* Reprinted with permission from Elsevier. Beard, J.A., A. Tenga, and T. Chen, The
interplay of NR4A receptors and the oncogene-tumor suppressor networks in cancer. Cell
Signal, 2015. 27(2): p. 257-66. doi: http://dx.doi.org/10.1016/j.cellsig.2014.11.009
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are mediators of cell cycle progression, apoptotic inhibition and reactive oxygen species
(ROS) regulation (Figure 2-1). In addition, loss-of-function studies of Nur77 have
demonstrated its importance in cell proliferation and survival [86], with the consensus
being that Nur77 knockdown reduces cellular growth rate and angiogenesis and induces
intrinsic and extrinsic apoptotic pathways. It is important to note that many loss-offunction studies are performed on non-stimulated cells to determine the role of basal,
endogenous Nur77. Conversely, in cells stimulated with various apoptosis-inducing
agents, Nur77 plays a role in cell death through both transcription-dependent and independent mechanisms (Figure 2-1). Because of the dual and opposite roles of Nur77
in cell proliferation and death, many studies have been focused on therapeutically
targeting Nur77 to impede its oncogenic functions while coaxing it to activate the cellular
death program [87]. These efforts would rely on the fact that non-tumor tissue will
express Nur77 at much lower levels, making these tissues less responsive to Nur77mediated apoptosis-inducing agents.
Nurr1 has been implicated in cancer progression although its cancer-related target
genes have not been characterized. Nurr1 knockdown decreases anchorage-independent
growth, suggesting that Nurr1 plays a role in cell transformation [88, 89]. The protein
promotes migration but not overall proliferation in bladder cancer [90], although it does
affect cell proliferation in lung and breast cancer [91, 92]. Nurr1 expression is higher in
squamous cell carcinoma (SCC) samples than in normal tissues of patients with SCC, and
induction of Nurr1 expression in SCC leads to increased resistance to 5-fluorouracil [93],
suggesting a role for Nurr1 in drug resistance [93, 94]. Additionally, Nurr1
overexpression contributes to protection from doxorubicin-induced apoptosis by
diminishing the p53 response [95].
In patients with breast cancer, Nurr1 expression in normal breast epithelium is
higher than that in tumor tissue and has been positively correlated with favorable
prognosis [92]. Conversely, the same study found that knockdown of Nurr1 in breast
cancer cell lines diminished xenograft tumor growth. The different roles of Nurr1 in
different tissues point to possible context-dependent effects of Nurr1, which might also
depend on the intracellular localization of Nurr1 protein as cytoplasmic expression of
Nurr1 in bladder cancer was correlated with decreased patient survival [90]. However,
other studies using either stimulated endogenous or overexpressed exogenous Nurr1 have
not clearly determined its subcellular localization.
Less is known about Nor-1’s functions in cancer, although some key findings
have been made. For example, Nr4a1−/−;Nr4a3−/− double-knockout mice develop acute
myeloid leukemia (AML) with very rapid onset, dying within 2 to 4 weeks [46]. The
myeloid cells from these mice have more S- and G2/M-phase populations and fewer
annexin V–positive cells than do those of wild-type mice. The decrease in apoptotic cells
was attributed to a reduction in extrinsic cell death signaling, as indicated by a decrease
in Fas ligand and TRAIL expression. Expression of Nur77 and Nor-1 were dramatically
reduced in AML patient samples. Together, these data suggest that these two NR4A
receptors can play overlapping tumor suppressive roles in leukemia, as NR4A singleknockout mice do not develop cancer [96, 97]. The functional redundancy of Nur77 and
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Figure 2-1. Nur77 mediates cell death or survival through localization-dependent
and –independent mechanisms.
As a nuclear transcription factor, Nur77 largely promotes cell proliferation and survival
through regulation of specific target genes (i.e., cyclin D2, E2F1, survivin, TXNDC5).
Additionally, some agonists of Nur77 transactivation are able to mediate transcriptiondependent cell death. A major mechanism of Nur77-mediated cell death is the nuclear
export of Nur77-RXRα heterodimers, which is suppressed by the CHD1L oncogene.
Cytoplasmic Nur77 can activate mitochondrial- or ER-associated cell death by interacting
with membrane-bound Bcl-2.
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Nor-1 was further confirmed in a follow-up study investigating genome-wide
transcriptional changes in response to NR4A restoration in AML [98]. Nur77 and Nor-1
shared overlapping gene signatures by regulating 97% of the same transcripts, and reexpression of either NR4A receptor was able to elicit tumor-suppressive functions by
reducing proliferation and increasing apoptosis. Furthermore, NR4A re-expression
suppressed MYC and its accompanying oncogenic signature in multiple AML cells.
Another perturbation of Nor-1 function occurs in extraskeletal myxoid
chondrosarcoma (EMC). Researchers identified a recurrent translocation of Nor-1 (also
called TEC, Translocated in Extraskeletal Chondrosarcoma) with the EWS gene that
encodes a novel EWS-TEC fusion protein in EMC tumors [99]. This oncogenic fusion
protein binds to and regulates the NGFI-B Response Element (NBRE), with 250-fold
greater transactivation capacity than that of wild-type Nor-1 [100]. Because EWS-TEC
fusion protein can bind to the NBRE, several studies have been focused on the
differential transactivation of target genes of EWS-TEC and Nor-1 [101, 102]. Analysis
of 16 EMC tumors showed that 15 cases contained EWS-TEC fusion transcripts [103].
Introduction of the EWS-TEC oncogenic fusion protein into a chondrogenic cell line did
not increase the proliferation rate but allowed cells to grow past contact inhibition to form
small clusters of cells and increased anchorage-independent growth [104]. Nor-1 also
forms fusion proteins with other proteins in EMC [105, 106].
NR4A Receptors and MAPK
MAPK and cancer
The mitogen-activated protein kinase (MAPK) pathway is induced by a wide
range of signals, including growth factors, cytokines, and stress, and is responsible for
almost every cell function, including proliferation, differentiation, cell death, and
migration. The six different MAPK pathways include extracellular signal-regulated
kinase (ERK) 1/2, ERK 3/4, ERK5, ERK 7/8, Jun N-terminal kinase (JNK) 1/2/3, and
p38 (ERK6), as reviewed in [107]. Typically, an external signal triggers the signaling
cascade through a membrane-bound receptor, followed by recruitment of G-proteins such
as Ras, Rac, and Rho and, subsequently, of downstream kinases such as Raf and MAPK
kinase kinase (MEKK), which phosphorylate and activate MAPK kinase (MEK).
Activated MEKs then phosphorylate and activate MAPKs [107], which will
phosphorylate either transcription factors to modulate target gene expression or other
kinases to regulate critical cellular events. Because the MAPK pathway is involved in
almost every cellular process, it is understandable that dysregulation of this pathway
could cause cancer.
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Regulation of NR4A receptors by MAPK
Phosphorylation of Nur77 by MEK-ERK signaling has been described by several
groups. Epidermal growth factor (EGF), an activating signal for ERK2, causes
phosphorylation of Nur77 at threonine 142 [108], a phosphorylation site that stabilizes
Nur77 [109], consistent with the phosphorylation-mediated stability of other nuclear
receptors. Interestingly, EGF enhances the interaction of Nur77 with prolyl isomerase
Pin1, and the isomerization of phosphorylated Nur77 requires ERK2- (and JNK1)mediated phosphorylation [110]. This phosphorylation-dependent isomerization prevents
degradation of Nur77, thereby increasing its transactivation activity and promoting its
pro-mitogenic effect. ERK2 is responsible for phosphorylation of Nur77 at serine 431, a
phospho-residue important for both the Nur77-Pin1 interaction and increased
transactivation mediated by Pin1.
ERK2 activation upon EGF treatment causes Nur77 nuclear localization and
prevents its cytosolic induction of apoptosis [111], but the opposite phenotype occurs in
T-cells. Inhibiting MEK1 decreases expression of Nur77 in T-cells [112] and prevents its
nuclear export and mitochondrial localization [113], demonstrating the role of ERK
signaling in Nur77-induced cell death. Ribosomal S6 kinase 2 (RSK2), an effector kinase
of MEK-ERK, phosphorylates Nur77 at serine 354 [113, 114] and positively regulates
Nur77’s nuclear export and subsequent mediation of apoptosis. Other groups have
reported phosphorylation of Nur77 by ERK5, but not by ERK2, in T-cells that caused
increased Nur77 transcription and induction of apoptosis [115, 116].
Activation of ERK1/2 signaling is positively associated with the nuclear
localization of Nur77 and negatively associated with the ability of fenretinide to induce
apoptosis [117]. Inhibiting MEK-ERK and treating with fenretinide enhance the cytosolic
localization of Nur77 in fenretinide-resistant HepG2 cells, but activating MEK-ERK
prevents this event in fenretinide-sensitive HuH-7 cells, demonstrating a role for ERK
signaling in the drug resistance of liver cancer cells. In another study, constitutive
signaling through BRAF-MEK-ERK was shown to positively regulate the expression of
both Nur77 and Nurr1 via inhibition of BRAF and MEK1/2 [118], implicating this
commonly mutated and hyperactive pathway as one of the causes of increased Nur77
levels in cancers. In addition, the p38 MAPK pathway can also modulate the activity of
Nurr1. For example, upon activation by apoptosis signal–regulating kinase 1, p38
phosphorylates Nurr1, leading to synthesis of melanin, a pigment important in protecting
skin, hair, and eyes from harmful elements [119].
In another study, fibroblast growth factor 8b (FGF-8b) induced the expression of
all three NR4As in MC3T3-E1 preosteoblastic cells [120]. Furthermore, the effect of
FGF-8b was mediated through the MAPK, phosphatidylinositol 3-kinase (PI3K), and
protein kinase C (PKC) pathways. Proliferation of these cells can be increased by FGF8b, and overexpression of Nur77 and Nurr1 further enhance this proliferative effect and
decrease apoptosis. Therefore, the MAPK pathways regulate the levels, sub-cellular
localizations, and activities of the NR4A receptors.
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NR4A Receptors, PI3K-AKT, and mTOR in Proliferation and Survival
PI3K-AKT and cancer
The PI3K-AKT signaling axis is a major regulator of cell proliferation and
survival, acting downstream of growth factors and receptor tyrosine kinases in parallel
with MAPK signaling [121]. PI3K heterodimers consist of regulatory and catalytic
subunits, which are responsible for PI3K regulation and downstream signaling,
respectively. Upon receptor tyrosine kinase activation and recruitment of PI3K to the
plasma membrane, the primary function of PI3K is to add a phosphate group to
phosphatidylinositol 4,5-bisphosphate (PIP2), converting it to phosphatidylinositol 3,4,5trisphosphate (PIP3) [122] to flip the “on” switch for downstream signaling. PIP3 recruits
AKT kinase to the plasma membrane, enabling its phosphorylation and activation by 3phosphoinositide-dependent protein kinase-1 (PDK1) [123, 124]. Conversely, AKT
signaling can be turned off through the phosphatase PTEN, which converts PIP3 back to
PIP2 [125, 126]. AKT can inhibit apoptosis to promote cell survival by phosphorylating
and inhibiting both pro-apoptotic Bad [127] and caspase-9 [128]; enhance cell-cycle
progression by phosphorylating and inactivating glycogen synthase kinase 3 beta
(GSK3B), leading to stabilization of cyclin D1 [129]; and increase cell growth by
stimulating the mechanistic target of rapamycin (mTOR) pathway to promote protein
synthesis [130].
Alterations in the PI3K-AKT pathway have been identified in various cancer
types and include mutations that directly increase PI3K and AKT activity [121, 131] and
inactivate the tumor suppressor PTEN [132-134]. Mice that are heterozygous for PTEN
develop an array of tumor types [135] due to uncontrolled PI3K-AKT signaling. Aberrant
AKT signaling can also lead to inactivation of tumor suppressor p53 [136], with the
hyperactivation of PI3K-AKT in cancer ultimately leading to increased cell survival and
proliferation and contributing to tumor growth, metastasis, and angiogenesis through
modulation of downstream effectors, including NR4A receptors.
The interplay of NR4A receptors and PI3K-AKT
AKT phosphorylates Nur77 [137-139] to negatively regulate its function in
mediating cell death. Specifically, AKT phosphorylates human Nur77 at Ser-351 (Ser350 in rats) in the DNA-binding domain [139], a phosphorylation site that inhibits Nur77
transcriptional activity [140]. AKT-mediated phosphorylation of Nur77 occurs in the
cytoplasm in a PI3K-dependent manner. More importantly, phosphorylation of Nur77 by
AKT decreases the transcriptional activity of Nur77 by 50%-85%. Additionally, the other
two NR4A members, Nurr1 and Nor-1, also have a similar phosphorylation motif, so it is
likely that AKT also phosphorylates Nurr1 and Nor-1, although this has not been
investigated. Furthermore, AKT directly inhibits Nur77’s DNA binding activity [138].
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In addition to inhibiting its DNA binding and transcriptional activity, AKT also
prevents Nur77 from inducing apoptosis in T-cell hybridomas [138]. To inhibit apoptosis
and increase cell survival, AKT phosphorylation of Nur77 can be considered to be a
“priming” step for an interaction with 14-3-3 protein, which recognizes the
phosphorylated motif near the Ser-351 residue. This protein-protein interaction, which
only occurs with wild-type Nur77 following AKT phosphorylation, is similar to AKTmediated phosphorylation of Bad and its subsequent interaction with 14-3-3: both
protein-protein interactions prevent the protein (Nur77 or Bad) from interacting with Bcl2 and causing subsequent apoptosis [127]. By using a DNA-binding domain deletion
mutant of Nur77 that readily localizes to the mitochondria and induces apoptosis [141],
researchers showed that overexpressing AKT blocks mitochondrial association with Bcl2 and causes a diffuse cytoplasmic localization of Nur77 [137]. Because the Nur77 DNAbinding domain deletion mutant lacks the Ser-351 residue, this experiment also showed
that AKT can phosphorylate cytoplasmic Nur77 at the N-terminus.
AKT can also act on nuclear Nur77, preventing its nuclear export and subsequent
apoptosis [137, 142]. Overexpression of constitutively active AKT can overcome the
effects of MEKK1-induced nuclear export of Nur77, retaining it within the nucleus [142].
The effect of AKT depends on Ser-351 of Nur77: if Ser-351 is replaced with alanine, the
Nur77 mutant migrates to and remains in the cytoplasm in response to MEKK1
activation, regardless of AKT status. Inhibition of PI3K-AKT or knockdown of AKT
restores Nur77’s cytoplasmic localization, whereas PI3K activation by insulin or AKT
overexpression efficiently blocks TPA-induced Nur77 nuclear export, cytochrome c
release, and apoptosis in gastric cancer cells [137]. In addition to Ser-351, the N-terminal
region of Nur77, specifically residues 51-105, are also shown critical for AKT binding
and phosphorylation-dependent regulation [137]. AKT’s inhibition of Nur77 has also
been credited with mediating cisplatin-induced apoptosis in ovarian cancer cells [143].
The interplay of NR4A receptors and mTOR
AKT acts on multiple downstream proteins, including the mTOR kinase complex
(mTORC1). The PI3K-AKT-mTOR axis could be considered to be a single pathway
[130] in which AKT activates mTOR to control cell proliferation and growth in response
to environmental stimuli by phosphorylating and inactivating the mTOR suppressors
tuberous sclerosis protein 1 (TSC1) and TSC2 [144, 145]. Another upstream negative
regulator of mTOR, liver kinase B1 (LKB1), activates AMP-activated protein kinase
(AMPK) [146] to suppress the mTORC1 complex [147]. PTEN also negatively regulates
mTOR by turning off PI3K-AKT signaling. The major effect of mTOR activation is
increased protein synthesis, leading to increased expression of proteins involved in
proliferation, survival, and angiogenesis [130].
Nur77 indirectly activates mTOR signaling by attenuating AMPK signaling, and
knockdown of Nur77 in non-small cell lung cancer cells decreased proliferation and
enhanced apoptosis [148]. Whereas AMPKα phosphorylation was increased and mTOR
phosphorylation decreased in that study, AKT phosphorylation status remained
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unchanged, suggesting that the effect on mTOR occurs downstream of AKT. A previous
microarray study by the same group demonstrated that sestrin-2 expression increased
after knockdown of Nur77 [50]. Sestrin-2, a target gene of p53 [149], serves to activate
AMPK signaling. Knowing that Nur77 has been shown to interact with and inhibit p53
[150], the authors further showed that knockdown of Nur77 enhanced sestrin-2–mediated
AMPK activation only in cells with wild-type p53. Further support for the role of Nur77
in mTOR activation comes in a report demonstrating Nur77’s suppression of AMPK
signaling [59], wherein knockdown or overexpression of Nur77 increased or decreased
AMPK phosphorylation, respectively. This relationship was not seen in LKB1-null HeLa
cells unless LKB1 was cotransfected with Nur77. Furthermore, Nur77-LBD interacts
with and sequesters LKB1 in the nucleus, away from cytoplasmic AMPK, leading to
decreased AMPK phosphorylation. A subsequent chemical screen found that the small
molecule ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) enhanced
AMPK phosphorylation by disrupting the Nur77-LKB1 interaction; this effect was not
seen in LKB1-null cells, further confirming LKB1-dependency. These studies
demonstrate interesting perspectives of Nur77 in which multiple signaling nodes are
interconnected through Nur77, as PI3K-AKT suppresses the pro-apoptotic functions of
Nur77 and Nur77 itself enhances downstream mTOR signaling to promote tumor
progression, possibly in the context of LKB1 or p53.
NR4A Receptors, Hypoxia, and Angiogenesis
HIF-1 and cancer
The hypoxia-inducible factors (HIFs) are a family of transcription factors that
mediate the balance of oxygen within tissues, having functions in multiple diseases, both
in protective and pathogenic roles [151]. At normoxic conditions (i.e., normal oxygen
levels), the HIF-1α subunit undergoes rapid proteolysis to maintain a low protein level,
and the HIF-1β subunit remains at a relatively constant level [152, 153]. The HIF-1α
subunit is maintained in its suppressed state by hydroxylation of specific prolyl residues
[154, 155], which promotes an interaction with the von Hippel-Lindau tumor suppressor
protein (pVHL) [156], a key protein responsible for targeting HIF-1α for proteasomal
degradation by recruiting ubiquitin ligases [157]. The suppression of HIF-1α is released
under hypoxic conditions (i.e., low oxygen levels) due to the unavailability of oxygen for
the hydroxylation step, leading to loss of pVHL recognition of HIF-1α and an
accumulation of HIF-1α protein. Additionally, a hydroxylation of HIF-1α by factorinhibiting HIF prevents binding of the coactivator p300 to the transactivation domain of
HIF-1α, preventing its transactivation [158]. Once at sufficient levels, HIF-1α migrates to
the nucleus where it forms a heterodimeric transcriptional complex with HIF-1β to
regulate the expression of target genes, including those encoding erythropoietin (EPO)
[159], vascular endothelial growth factor (VEGF) [160], and proteins involved in glucose
uptake and metabolism [161-164]. The HIF-1 transcription factors are able to mediate
key processes within hypoxic regions deep within newly established tumor sites to
control the balance of oxygen consumption and oxygen delivery. HIF-1 effectively
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controls these processes by regulating the expression of hundreds of genes, many of
which are involved in proliferation, metabolic adaption, and angiogenesis [165, 166],
which are key hallmarks of cancer [167]. As summarized by Semenza [165], loss-offunction and gain-of-function studies have revealed that the HIF-1 target gene products
are tumor-promoting and, thus, increase proliferation, angiogenesis, and metastasis in
multiple tumor models. Many primary tumors and metastases have increased HIF-1
activation as indicated by increased staining of the HIF-1 protein in tissue samples when
compared to adjacent normal tissue [168, 169], and its expression is associated with
increased tumor vascularization and aggressiveness [170]. Increased HIF-1α expression
and activity in cancer can be attributed to cancer-associated hypoxia, loss of tumor
suppressor function (i.e. pVHL, p53 or PTEN), or contributions of growth factor or
oncogene signaling (i.e. PI3K or MAPK), either through blocking degradation or
enhancing synthesis of HIF-1α [166]. Patients with clear cell renal carcinoma and loss of
pVHL have enhanced HIF-1α expression due to the decreased degradation of HIF-1α,
defining pVHL as a tumor suppressor [171, 172].
The interplay of NR4A receptors and HIF-1
Hypoxia increases the expression of all three NR4A family members at both
mRNA and protein levels in a HIF-1α–dependent manner [173-177]. HIF-1α, but not
HIF-2α, can directly regulate Nur77 and Nor-1 expression by binding to hypoxiaresponse elements in each gene’s promoter [173, 174, 176]. Additionally, the Nur77
target gene proopiomelanocortin (POMC) is induced under hypoxic conditions through
HIF-1α–dependent regulation of Nur77. Furthermore, Nur77 itself regulates HIF-1α,
implicating this as a possible feedback mechanism in cancer progression. Expression of
wild-type but not of dominant negative Nur77 can activate a hypoxia response element–
containing promoter, increasing nuclear localization of HIF-1α [174, 178]. Additionally,
when examining this HIF-1 response to Nur77, the HIF-1 target gene VEGF increased at
both the mRNA and protein levels, but HIF-1α increased at only the protein level and
underwent attenuated ubiquitination [174, 178], suggesting stabilization of
transcriptionally active HIF-1α by Nur77. Two reports have suggested different Nur77
domains as being requirements for HIF-1α stabilization and transactivation, either
through the N-terminal [174] or ligand-binding domain [178]. These domain-specific
stabilizations of HIF-1α depend on different Nur77 protein interactions, although neither
affects HIF-1α binding with pVHL. The N-terminal domain of Nur77 can block Mdm2
from binding to and degrading HIF-1α and also leads to decreased Mdm2 expression
[174]. However, another group demonstrated that Nur77-LBD can interact with the αdomain of pVHL, forcing elongin C dissociation and blocking pVHL-mediated
degradation of HIF-1α [178]. The fact that pVHL was required for Nur77-mediated
stabilization indicates that pVHL serves as an adaptor protein to form a Nur77-pVHLHIF-1α complex. Interestingly, Nurr1 and Nor-1 positively regulate HIF-1α expression
[175, 178], and HIF-1α–induced Nor-1 protects endothelial cells exposed to hypoxia,
possibly by regulating cellular inhibitor of apoptosis 2 [176].
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The regulation and function of Nur77 within hypoxic environments may be
critical factors to consider and are addressed by a recent report showing crosstalk
between Nur77 and β-catenin signaling during hypoxia [177], in which both were
induced and required to positively regulate each other through transcription-independent
mechanisms. Although Nur77 is typically considered to be a nuclear protein that
regulates target gene expression in the context of cancer, hypoxia-induced Nur77 is
highly expressed in the cytoplasm, and this localization is required for stabilization of βcatenin [177]. This finding is similar to one in bladder cancer patients that indicated
cytoplasmic Nurr1 level was correlated with poor prognosis, although other possible
factors were not described [90]. Hypoxia can increase AKT phosphorylation in a Nur77dependent manner [177], presenting a unique regulatory mechanism, as Nur77 is
phosphorylated by AKT to prevent its mitochondrial localization [137], thus preventing
cell death and enhancing its pro-oncogenic functions. The feed-forward loop of Nur77
and β-catenin promotes cell growth, migration, and invasion and alters epithelial-tomesenchymal transition (EMT) markers [177]. Together, these studies reveal that
hypoxia affects both the level and function of NR4A receptors, which in turn play
positive feedback roles that affect hypoxia-induced signaling.
NR4A receptors as mediators of VEGF-induced angiogenesis
Given the reported roles of the NR4A receptors in hypoxia, a reasonable
hypothesis might be that hypoxia-induced upregulation of NR4A receptors will positively
regulate HIF-1α, thus increasing HIF-1–regulated genes and promoting survival,
angiogenesis, and tumor promotion. The anti-metabolite 6-mercaptopurine (6-MP),
known to increase NR4A transactivation through its AF-1 domain [179], induces the
expression of all three NR4A members, HIF-1α, and VEGF and increases the stability,
nuclear localization, and transactivation of HIF-1α protein in a Nur77-dependent manner
[175]. The effects of 6-MP on NR4A and HIF-1α depend on p44/p42 ERK
phosphorylation and can be abolished using a MEK inhibitor, a previously reported
regulatory mechanism of Nur77 in hypoxia [174]. Furthermore, 6-MP enhances the HIF1α response in endothelial cells and promotes capillary tube formation [175], indicating
that induction of Nur77 and its regulation of HIF-1α can promote angiogenesis.
One main mediator of angiogenesis is VEGF, which is induced by deoxycholic
acid (DCA) through enhancing the expression of Nur77 in colon cancer cells [180].
VEGF stimulation of cells rapidly induces expression of all three NR4A members [181184], which mediate VEGF-induced effects on proliferation and angiogenesis. Similar to
VEGF, Nur77 expression increases the proliferative rate of endothelial cells and protects
cells from apoptosis [183], suggesting that VEGF exerts its effect by upregulating Nur77
expression. Nur77 knockdown increases apoptosis, which cannot be rescued by addition
of VEGF, further suggesting that Nur77 operates downstream of VEGF in this context. In
addition, the effect of VEGF depends on Nur77, and both VEGF and Nur77 induce the
expression of the cell cycle–related genes cyclin A, cyclin D1, proliferating cell nuclear
antigen (PCNA), and E2F [183]. Inactivation of Nur77 reduces capillary tube formation,
and mutants lacking the DNA-binding domain undergo no tube formation [183].
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Compared to wild-type mice, Nur77−/− mice form fewer xenograft tumors, with reduced
angiogenesis within the tumors [183]. These data suggest that VEGF-induced
angiogenesis is mediated through Nur77.
Induction of Nor-1 by VEGF has been attributed to VEGF receptor 2 (VEGFR-2),
and its expression is modulated at the Nor-1 promoter through CBP [182]. Knockdown of
Nor-1 in endothelial cells attenuates DNA synthesis and progression of cells into S-phase
following VEGF stimulation, suggesting that Nor-1 mediates the effects of VEGF and
confirming a previous finding of Nor-1’s role in vascular smooth muscle proliferation
[185]. Similarly, VEGF-induced Nurr1 expression occurs rapidly, within 1 hour, and is
mediated at the promoter level by NF-κB and CREB response elements [184]. Upon
VEGF stimulation, CREB becomes phosphorylated and binds to the Nurr1 promoter, and
this action can be blocked by inhibiting protein kinase D. Nurr1 knockdown can inhibit
VEGF-mediated proliferation, migration, and in vivo angiogenesis [184]. These studies
demonstrate that NR4A receptors are critical mediators of VEGF-mediated signaling.
NR4A Receptors, p53, and Cell Death
p53 and cancer
As the main arbitrator of determining cell cycle progression, DNA repair, and
apoptosis, the tumor suppressor p53 is a central hub in regulating cell fate [186, 187]. In
response to a stress stimulus, such as DNA damage, p53 is quickly induced. Induction of
p53 typically occurs at the protein level through inhibition of p53 degradation, known as
derepression, by the blocking of a critical ubiquitination by the E3 ligase Mdm2 and,
ultimately, the enhancement of p53 protein stability. With increased p53 protein levels,
the cell’s fate can now be regulated by tetramerization of p53 proteins and transcription
of target genes. For example, p53 can drive the expression of cyclin-dependent kinase
p21 [188, 189] and Gadd45 [190] to block cell-cycle progression, allowing the cell
enough time to undergo DNA repair to correct any lesions. If the damage received proves
to be too extensive, then p53 can initiate the cell death program through induction of
genes such as Puma [191], Noxa [192], and Bax [193] to prevent the outgrowth of cells
with damaged genomes. Additionally, p53 can execute the cell death program through
DNA-binding–independent mechanisms by forming complexes with other signaling
molecules such as B-cell lymphoma 2 (Bcl-2) at the mitochondrial membrane, which
compromises the integrity of the outer mitochondrial membrane, resulting in cytochrome
c release [194]. Through these multiple mechanisms of halting cell expansion, p53 serves
as a critical tumor suppressor to prevent the formation of malignant lesions.
Since the discovery of p53, an overwhelming amount of reports have suggested
that somatic p53 mutations occur in at least half of all cancers, with higher frequencies in
certain malignancies, making it the most commonly mutated gene in cancer [195].
Mutations of p53, which commonly occur in its DNA-binding domain, serve to hijack its
function as a tumor suppressor, making cells vulnerable to malignant transformation.

21

Also, because many p53 mutations occur in the DNA-binding domain, mutated p53,
acting in a dominant-negative manner, is still able to form tetramers with wild-type p53
protein to render them inactive [196]. Accumulating evidence also points to oncogenic
functions of mutated p53 [197]. Additionally, in cancers with wild-type p53, the function
of p53 can still be altered through overexpression of the negative regulator Mdm2 [198].
The importance of p53 in tumor suppression is evident in studies of p53 knockout mice in
which all mice lacking p53 eventually succumb to disease, mostly due to sarcomas and
lymphomas [199].
The interplay of NR4A receptors and p53
Both Nur77 and Nurr1 interact with p53 and regulate critical p53-dependent
signaling, which could at least partially explain the oncogenic functions of NR4A
receptors. On the heels of a finding that Nur77 could mediate Mdm2 degradation to
promote HIF-1α stabilization [174] despite the lack of a Nur77-Mdm2 interaction, a
direct interaction of Nur77 with p53 was demonstrated [150] that could explain this
negative regulation of Mdm2. The Nur77-p53 interaction leads to a blockade of p53
acetylation, resulting in loss of p53-dependent transactivation and subsequent decreased
expression of the target genes Mdm2 and cyclin-dependent kinase inhibitor p21.
Interestingly, Nur77 can enhance p53-dependent apoptosis with and without UV
irradiation, suggesting non-genomic regulation within the Mdm2-p53 axis. Ubiquitination
of p53 by Mdm2 is also obstructed by Nur77, enhancing its stability. The results of these
studies suggest that the pool of available p53 protein might play an important role in its
transcriptional regulation, protection from Mdm2-mediated destruction, and enhancement
of apoptosis conferred by Nur77. More recent findings show that the Nur77-mediated
enhancement of p53-dependent apoptosis is due to phosphorylation of Nur77 by DNAdependent protein kinase (DNA-PK) [200]. This phosphorylation of Nur77 enhances that
of p53 by DNA-PK and, ultimately, increases the potential for induction of apoptosis
upon DNA damage.
Similarly, Nurr1 interacts with p53 and inhibits p53-dependent apoptosis by
inhibiting transactivation [95]. Nurr1 interacts with the C-terminal domain of p53 to
attenuate doxorubicin-induced expression of the proapoptotic protein Bax, and cells
lacking p53 do not exhibit doxorubicin resistance in the presence of Nurr1. The effects of
Nurr1 on p53 are attributed to a reduction in the tetramerization of p53, which is required
for its transcriptional activity. Although Nurr1 also has roles in DNA-PK–mediated DNA
repair [201], the role of a Nurr1-p53 interaction in this process is unknown. Interestingly,
a recent study found Nurr1 expression to be inversely correlated with p53 expression in
primary breast cancer tissues [92]. The effects of p53 interaction with Nurr1, and Nur77
likewise, have not been addressed, and it remains to be determined whether p53 can
interfere with the oncogenic effects of the NR4A receptors through direct protein
interactions or other signaling mechanisms.
NR4A receptors not only affect the immediate responses of p53 but also affect
other downstream pathways in a p53-dependent context. One such pathway is the
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AMPK-mTOR axis. As discussed in section 4.3, Nur77 can indirectly activate mTORC1
signaling by inhibiting p53 [148]. In p53 wild-type cells, but not in p53-null cells, Nur77
inhibited p53-mediated transactivation of the sestrin-2 promoter and subsequent
expression of sestrin-2, a known target of p53 that inhibits mTOR signaling [149].
Nur77 in cell death
An intricate review by Moll and colleagues [202] draws parallels between p53
and Nur77 as cell death mediators that act through the intrinsic cell death pathway.
Regardless of the route in which p53 activates cell death (i.e., transcription-dependent or
-independent), the ultimate outcome is a mitochondria-induced cell death either through
p53 target genes such as PUMA or BAX or through direct interactions with other
molecules such as Bcl-2 at the mitochondrial outer membrane. Similarly, increasing
evidence points to multiple mechanisms of Nur77-mediated cell death through nuclear
and cytosolic Nur77 functions (Figure 2-1). A well-characterized mechanism of Nur77mediated cell death is that in which Nur77 translocates from the nucleus to begin the
apoptosis cascade, independently of transactivation, in response to certain death-inducing
compounds [56, 203]. Nur77 heterodimerizes with retinoid X receptor (RXR) alpha and
translocates from the nucleus to the cytosol, where the complex can target the
mitochondria [204-206]. Bcl-2, a protein that is anti-apoptotic under most conditions,
serves as a receptor on the mitochondrial outer membrane and is the downstream effector
of Nur77 through an interaction with its ligand-binding domain [207]. Anti-apoptotic
Bcl-2 is converted to a pro-apoptotic molecule through a conformational change of its
Bcl-2 homology (BH) domains after Nur77 binding [207]. The conformational change
exposes the buried pro-apoptotic BH3 domain of Bcl-2, resulting in a release of
cytochrome c [141] and further activation of apoptosis. Deletion of the BH3 domain of
Bcl-2 inhibits Nur77-mediated apoptosis. Another report suggests that Nur77 can mediate
stress-induced apoptosis by targeting Bcl-2 at the endoplasmic reticulum (ER), leading to
a release and depletion of ER calcium and activation of caspase-4 and -8 [208].
Therefore, cytosolic Nur77, by interacting with Bcl-2 either at the mitochondrial outer
membrane or ER, is pro-apoptotic.
Although Nur77 exerts its pro-apoptotic effect largely through a translocationdependent mechanism, it also regulates specific target genes involved in cell cycle
regulation, survival, and apoptosis. Therefore, small-molecule agonists [49-55] or
antagonists [47-49] of Nur77 could be useful in modulating its transcription factor
functions. One group has identified methylene-substituted diindolylmethanes (DIMs) as
being agonists or antagonists of Nur77 and has shown that in vitro and in vivo treatment
of colon, pancreatic, and bladder cancer cells with DIM-C-pPhOCH3 activates Nur77
through its ligand-binding domain [49], leading to growth inhibition, cell cycle arrest,
and/or cell death [49-53]. Treatment with DIM-C-pPhOCH3 causes a Nur77-dependent
increase in TNF-related apoptosis-inducing ligand (TRAIL/TNFSF10), p21, and other
genes, implicating DIM-C-pPhOCH3 in regulating the cell cycle and apoptosis [49-52]
(Table 2-1). The DIM-C-pPhOCH3–mediated effects are independent of Nur77’s
translocation to mitochondria, and Nur77 remains localized within the nucleus. TRAIL is
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Table 2-1.

Summary of gene expression changes after treatment with NR4A agonists or antagonists.
Compound

Symbol
ATF3
ATF4
BCL2
BIRC5
BRE
CDKN1A
DDIT3

MYC

CTH
DUSP1
EGFR

Action

Direction

Method

Agonist

Increased

M, G
M, G, P

NR4Adependent?
No
Yes; Nur77

Antagonist

Increased

P

Antagonist

Decreased

DIM-CpPhOH

Antagonist

Cytosporone
B

Gene name

Name

Activating
transcription factor 3
Activating
transcription factor 4

DIM-CpPhOCH3
DIM-CpPhOH
DIM-CpPhOH

B-cell lymphoma 2
Baculoviral IAP
repeat containing 5
(Survivin)
Brain and
reproductive organexpressed
Cyclin-dependent
kinase inhibitor 1A
(p21, Cip1)
DNA-damageinducible transcript 3
(CHOP)
V-Myc avian
myelocytomatosis
viral oncogene
homolog (c-Myc)
Cystathionase
(cystathionine
gamma-lyase)
Dual specificity
phosphatase 1
Epidermal growth
factor receptor

Detection
Direct?

Cancer type

Ref

n.d.
n.d.

Colon
Pancreatic

51
53

Yes; Nur77

n.d.

Pancreatic

48

P

n.d.

n.d.

Pancreatic,
Lung

47, 148

Decreased

G, P, R, C

Yes; Nur77

Yes

Pancreatic,
Lung

47, 148

Agonist

Decreased

M, G, P, R, C

Yes; Nur77

Yes

Gastric

54

Agonist

Increased

M, G, P, R, C

Yes; Nur77

Yes

Agonist

Increased

G

n.d.

n.d.

Pancreatic,
Bladder
Pancreatic

DIM-CpPhOH

Antagonist

Increased

G, P

Yes; Nur77

n.d.

Pancreatic

48

DIM-CpPhOH

Antagonist

Decreased

P

n.d.

n.d.

Lung

148

DIM-CpPhOCH3

M, G

No

n.d.

Increased

M, G

Yes; Nur77

n.d.

Colon
Bladder,
Pancreatic

51

Agonist
Agonist

Increased

M, G

Yes; Nur77

n.d.

Pancreatic

53

Antagonist

Decreased

P

n.d.

n.d.

Lung

148

DIM-CpPhOCH3
DIM-C-Ph

DIM-CpPhOCH3
DIM-CpPhOH
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50, 52, 53
52

50, 53

Table 2-1.

(Continued).
Compound

Symbol
FASLG
GDF15
PDCD1
NUPR1

SESN2

TNFSF10

TXNDC5
XBP1

Gene name
Fas ligand (TNF
superfamily, member
6)
Growth
differentiation factor
15 (NAG-1)
Programmed cell
death 1
Nuclear protein,
transcriptional
regulator 1 (p8)
Sestrin 2

Tumor necrosis
factor (ligand)
superfamily, member
10 (TRAIL)

Thioredoxin domain
containing 5
X-box binding
protein 1

Detection

Name

Action

Direction

Method

NR4Adependent?

Direct?

Cancer type

Ref

DIM-CpPhOCH3

Agonist

Increased

P

Yes; Nur77

n.d.

Pancreatic

53

DIM-CpPhOCH3

Agonist

Increased

M, G

No

n.d.

Bladder,
Pancreatic

50, 53

DIM-CpPhOCH3

Agonist

Increased

M, G

Yes; Nur77

n.d.

Colon

51

DIM-CpPhOCH3

Agonist

Increased

M, G

Yes; Nur77

n.d.

Bladder

50

Agonist

Increased

M, G

Yes; Nur77

n.d.

Bladder

50

Antagonist

Increased

G, P, R, C

Yes; Nur77

No

Lung

148

DIM-CpPhOCH3

Agonist

Increased

G, P

Yes; Nur77

n.d.

Pancreatic,
Colon,
Bladder

50, 49, 51,
53

DIM-CpPhCH3

Agonist

Increased

P

n.d.

n.d.

Pancreatic

49

DIM-C-Ph

Agonist

Increased

G, P

n.d.

n.d.

Pancreatic,
Colon,
Bladder

50, 49, 51

Agonist

Increased

G, P

Yes; Nurr1

n.d.

Bladder

209

Antagonist

Decreased

M, G, P, R, C

Yes; Nur77

Yes

Pancreatic

48

Antagonist

Increased

P

Yes; Nur77

n.d.

Pancreatic

48

DIM-CpPhOCH3
DIM-CpPhOH

DIM-CpPhCl
DIM-CpPhOH
DIM-CpPhOH

Detection key: M = microarray, G = gene, P = protein, R = promoter reporter, C = chromatin IP; n.d. = not determined
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implicated in the extrinsic pathway of apoptosis, a cell death pathway that bypasses the
intrinsic mitochondrial pathway, further supporting a translocation-independent
mechanism. As expected, cleavage of caspase-8 is detected after treatment with DIM-CpPhOCH3 [49-51, 53]. Another compound in this series of DIM analogs, DIM-C-pPhOH,
is described as a Nur77 antagonist, capable of inhibiting both basal and agonist-induced
Nur77 transactivation through its N-terminal domain [47-49, 52]. Interestingly, DIM-CpPhOH can also inhibit in vitro and in vivo cancer cell growth and induce apoptosis [4749, 148], mimicking the effects seen after RNAi-mediated knockdown of Nur77,
primarily through a Nur77-dependent regulation of target gene BIRC5/Survivin
(Table 2-1). Nur77 knockdown or DIM-C-pPhOH treatment also cause morphological
changes indicative of ER stress, which are accompanied by upregulation of ER stress
genes and proteins (Table 2-1) and downregulation of the Nur77 target gene TXNDC5, a
gene responsible for maintaining proper ROS levels [48]. The structure-dependent effects
of C-DIMs on Nur77-regulated pro-apoptotic and anti-apoptotic genes, although not
completely straightforward, are attributed to interactions with specific cofactors (i.e.,
p300) and other transcription factors (i.e., Sp1) [47, 52], but other genes are regulated
through direct NBRE- and NuRE-binding sites.
Another DIM analog, DIM-C-pPhCl, was found to be a Nurr1-specific agonist
[209]. This compound can inhibit TRAIL induction, apoptosis, and proliferation of
bladder cancer cell lines, can block in vivo tumor growth, and can increase overall
survival. These data suggest that Nurr1, similar to Nur77, may regulate both proliferative
and survival genes (or death-inducing genes) depending on specific stimuli or structuredependent small-molecule features and that agonists or antagonists could be developed to
regulate this orphan receptor.
The small-molecule natural product cytosporone B (Csn-B) and its analogs are
also ligands for the Nur77 ligand-binding domain [54, 55]. Csn-B stimulates Nur77’s
transcriptional activity through an interaction with Tyr-453 without affecting the activity
of other NRs. A critical hydrogen bond is formed between a hydroxyl group of Csn-B
(and its analogs) and Nur77 at Tyr-453 [54]. The series of analogs depend upon Nur77 in
mediating apoptosis, which is induced by the translocation of Nur77 to the mitochondria
after activation of the intrinsic pathway of apoptosis [55]. Csn-B and analogs suppress the
expression of brain and reproductive organ–expressed protein (BRE), an anti-apoptotic
protein. The promoter of BRE contains a binding site for Nur77, suggesting that
modulation of nuclear Nur77 may suppress genes containing NBRE or NuRE in their
promoter, possibly by recruiting corepressors (i.e., nuclear receptor co-repressor-1).
Nur77 can also upregulate BRE in colon cancer cells after DCA treatment [180].
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NR4A, Wnt, and β-catenin
Wnt and cancer
The roles of Wnt signaling in cancer have been previously reviewed [210, 211].
Wnt binds to and activates a Frizzled receptor, which then interacts with the intracellular
Dishevelled to activate downstream events, including the canonical (i.e., β-catenin–
dependent) and non-canonical Wnt pathways [211]. In the canonical pathway, β-catenin
accumulates within the cytoplasm and translocates to the nucleus, where it acts as a
transcriptional coactivator of the TCF/LEF family of transcription factors. TCF/LEF then
targets genes involved in cell proliferation, stem cell maintenance, and differentiation.
These target genes include those of cyclin D1 and c-Myc, which are required for the
transition from G1 to S phase in the cell cycle. In the absence of Wnt signaling, β-catenin
is normally degraded by a complex of proteins including Axin, adenomatosis polyposis
coli (APC), Glycogen synthase kinase 3β (GSK3β), and casein kinase 1α (CK1α). These
proteins mediate phosphorylation of β-catenin, leading to ubiquitination and subsequent
proteasomal degradation, thus preventing β-catenin from accumulating in the cytoplasm
and performing its coactivator function.
Dysregulation of Wnt signaling has been linked to cancer development [210].
Wnt1 ligand is a proto-oncogene in a mouse model of breast cancer. Multiple signaling
dysregulations lead to elevated β-catenin, which is strongly correlated with poor
prognosis of breast cancer patients, and have been implicated in other cancers such as
colorectal cancer, melanoma, prostate cancer, lung cancer, glioblastoma, esophageal
cancer, ovarian cancer, and familial adenomatous polyposis. The initial consensus was
that increased Wnt signaling always correlates with negative patient outcomes, however
recent evidence shows otherwise. Enhanced Wnt signaling can either promote or inhibit
cancer formation and progression, and this is strongly dependent on the type and stage of
cancer.
The interplay of NR4A receptors and Wnt signaling
Nuclear receptors, including the NR4A receptors, modulate the Wnt pathway
[212, 213]. Nurr1 inhibits Wnt signaling by blocking β-catenin transactivation in both
293F and MC3TC-E1 osteoblastic cells. A similar observation was made in U2OS
osteosarcoma cells in which the NR4A receptors block the transcriptional activity of βcatenin through a mechanism involving the DNA-binding domain of the NR4A receptors
[213]. In addition, Nur77 promotes β-catenin degradation in the cytoplasm and inhibits
tumor formation in vivo through transcriptional inhibition of the Wnt pathway [84, 214].
This finding would seem contradictory because Nur77 is overexpressed in most solid
tumors; however, analysis of tissue samples from patients with colon cancer revealed that
Nur77 is hyperphosphorylated by GSK-3β, which may impede its inhibition of the Wnt
pathway [214]. Conversely, the NR4A receptors can indirectly increase β-catenin in
melanoma cells. Nur77 targets CBP/p300-interacting transactivator 1 (CITED1) and
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Nur77/Nurr1 targets Dishevelled-binding antagonist of beta-catenin 1 (DACT1), both of
which are negative regulators of the Wnt pathway. CITED1 inhibits β-catenin
transactivation, and DACT1 interacts with the Wnt activator Dishevelled to promote its
degradation, leading to inhibition of the Wnt pathway [118]. Therefore, NR4A receptors
inhibit CITED1 and DACT1 to increase Wnt activity.
Alternatively, the Wnt pathway can either upregulate or repress the NR4A
receptors depending on the cellular context. In 293F cells, β-catenin and Nurr1 directly
bind, disrupting an interaction with the corepressor Lef-1. This enables Nurr1 and βcatenin to activate their transcriptional targets. This interaction is important for normal
neuron development and the survival of dopaminergic neurons [84, 213]. Nur77 can also
be upregulated upon the addition of the colon carcinogen DCA, which stabilizes βcatenin and allows it to form a transcriptional complex with AP-1 that can then bind to
the Nur77 promoter to enhance transcription of Nur77 [84, 213, 214]. Conversely,
overexpression of β-catenin in U2OS and HeLa cells inhibits NR4A transcriptional
activity through a mechanism involving the ligand-binding domain of the NR4A
receptors [213].
As discussed in section 5.2, a positive feedback loop between Nur77 and βcatenin has been identified under hypoxic conditions in colorectal cancer cells [177]. βcatenin induces Nur77 expression through HIF-1α. However, Nur77 can increase βcatenin’s protein levels by increasing its half-life in the cytoplasm. Furthermore, the
growth, migration, and invasion of colorectal cancer cells increase upon overexpression
of β-catenin or Nur77, and these effects are further enhanced when β-catenin and Nur77
are coexpressed. The authors of these findings argued that previous studies on the
interaction between Nur77 and β-catenin are conflicting because of the normoxic
conditions used in those studies and that it is, therefore, more realistic to perform these
experiments under hypoxic conditions, which more closely mimic the environment of a
tumor. Overall, it is clear that the tissue type and environmental conditions play an
important role in how NR4A receptors interact with the Wnt pathway.
CHD1L Oncogene and Nur77
CHD1L and cancer
Chromodomain helicase/ATPase DNA binding protein 1-like, or CHD1L, is a
member of the Snf2-like family of chromatin remodelers and modifiers [215]. Unlike
other members of this family, CHD1L does not contain a chromodomain that recognizes
methylated histone tails but, instead, harbors a macro domain containing a Poly (ADPribose) (PAR)-binding element [216], which allows binding with Parp1 [217, 218].
Several groups have shown that CHD1L has macro domain–dependent ATPase activity
in the presence of DNA and nucleosomes that is enhanced by Parp1 [217, 218]. CHD1L
also interacts with proteins involved in DNA repair in a Parp1-dependent manner and is
recruited to DNA damage break points through its macro domain [217, 218]. In addition

28

to its function in chromatin remodeling and DNA repair, CHD1L also has DNA-binding
and transcription factor capabilities [219]. Confirmed target genes of CHD1L include
ARHGEF9 [219], TCTP [220] and SPOCK1 [221].
The CHD1L gene, also called ALC1 (Amplified in Liver Cancer 1), is an
oncogene, residing in the frequent 1q21 amplicon found in some solid tumors [222],
including hepatocellular carcinoma (HCC) [223, 224]; amplification of the 1q21 locus
has been found in 58%-78% of HCC cases [224, 225]. Gain-of-function and loss-offunction studies have confirmed the role of CHD1L as an oncogene, having the ability to
enhance in vitro cell transformation and in vivo tumor formation and tumor size, which
can be attributed to its ability to promote the G1/S phase transition [224]. In addition to
its growth-promoting effects, CHD1L can protect cells from apoptosis [224] and 5fluorouracil [226]. Analyses of patient samples revealed that approximately 50% of
patients with HCC have CHD1L overexpression [224, 226] and that 68% of metastatic
tumor sites have higher levels of CHD1L than are found in the matching primary tumors
[219]. Indeed, overexpression of CHD1L is associated with resistance to chemotherapy in
patients with HCC [226]. Studies of CHD1L-transgenic mice further demonstrate the
oncogenic ability of CHD1L, with about 25% of mice forming spontaneous tumors,
including some cases of HCC [227].
The effects of CHD1L on oncogenesis can be attributed to its transcription factor
function and target genes. The first target gene identified for CHD1L was ARHGEF9
[219], a guanine nucleotide exchange factor that activates Cdc42, which is a GTPase
involved in epithelial-to-mesenchymal transition (EMT) and metastasis [228]. Indeed,
CHD1L overexpression can induce an AHGEF9-Cdc42–dependent EMT, resulting in
increased in vivo tumor invasiveness and metastasis. Target gene TCTP is overexpressed
in about 40% of HCC patient samples and is associated with advanced tumor stage; its
overexpression increases in vivo tumor formation via faster mitotic exit and cell division
[220]. Similarly, CHD1L target gene SPOCK1 is associated with clinical stage and
metastasis and can protect cells from staurosporine-induced apoptosis in an AKTdependent manner [221].
The interplay of Nur77 and CHD1L
Recent evidence demonstrates that Nur77 interacts directly with the CHD1L
protein [229]. The C-terminal macro domain of CHD1L interacts with Nur77, inhibiting
its nuclear-to-mitochondrial translocation and subsequent induction of apoptosis. CHD1L
expression in a panel of HCC cell lines negatively correlates with induction of apoptosis
following staurosporine treatment, further supporting CHD1L’s role as an inhibitor of
apoptosis and a potential mediator of drug resistance. It remains to be determined which
residues of Nur77 are critical in the interaction with CHD1L and whether this interaction
prevents binding of other proteins, such as RXR, or specific post-translational
modifications of Nur77. Additionally, CHD1L is involved in chromatin remodeling and
DNA repair [217, 218], which is mediated by its C-terminal macro domain through
interactions with Ku70 and DNA-dependent protein kinase, catalytic subunit (DNA-
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PKcs). Given that Nur77 interacts with Ku80 to suppress DNA repair [200], it is
plausible that a Nur77-CHD1L interaction could also repress chromatin remodeling and
subsequent DNA repair, making the interaction mutually inhibitory. Also of interest is
that CHD1L-mediated expression of SPOCK1 can activate AKT to maintain
mitochondrial membrane potential, which prevents cytochrome c release and apoptosis,
all of which is blocked by pretreatment with an AKT1 inhibitor [221]. This scenario
raises the possibility that CHD1L might inhibit Nur77 translocation through both a direct
protein-protein interaction and through activation of AKT, which is known to be
inhibitory to Nur77’s mitochondrial association [137]. The regulation of Nur77 by
CHD1L might offer a useful therapeutic avenue in which a small molecule could be
developed to disrupt this interaction, allowing Nur77 to become fully functional in the
cell death program.
Concluding Remarks
In summary, the NR4A family, represented by three highly homologous orphan
receptors, plays multiple roles in cancer, with most studies highlighting the prooncogenic functions of Nur77 and Nurr1. In addition, Nur77 and Nor-1 have been
characterized as being tumor suppressors in AML, likely due to their regulation of
apoptosis in hematopoietic cells. This finding, in combination with other confounding
results, as indicated by overexpression or downregulation in cancer cell lines and patient
samples, shows the need to determine the cellular context in which the NR4A receptors
contribute to oncogenesis or tumor suppression. It appears that multiple nuances can
determine the role of NR4As in cancer, including but not limited to cell and tissue type,
subcellular localization, external stimuli, protein-protein interactions, and posttranslational modifications.
The NR4A family is intertwined with many relevant cancer signaling pathways,
which likely explains the dysregulated expression of these NRs in cancer, as well as their
functions in tumorigenic hallmarks, including proliferation and survival (Figure 2-2). As
an emerging research topic, it is highly likely that microRNAs are able to regulate the
expression of NR4As in cancer, making their regulation and function much more
interesting yet complex. Determining the contributions of microRNAs to NR4A
regulation would provide further insight into NR4A dysregulation, as it is likely that a
deleted or silenced tumor suppressor–like microRNA could target NR4A, explaining the
general consensus of NR4A overexpression. Restoration of microRNA expression by
using chemically modified and/or lipid-encapsulated mimics could lead to suppressed
NR4A expression, ultimately reducing proliferation and inducing apoptosis.
Lastly, due to its dual functions in cell proliferation and death, Nur77 remains a
unique drug target that several groups are targeting using small molecule approaches.
One promising approach using small molecules would be to target the Nur77-CHD1L
interface in hepatocellular carcinoma with 1q21 amplification to release nuclear-retained
Nur77 from CHD1L; presumably, this type of small molecule could be used in
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Figure 2-2. The NR4A family and key signaling pathways regulate each other.
Both the expression and function of the NR4A members are mediated by activation or
inhibition of multiple signaling pathways. Growth factor signaling upregulates the
expression and nuclear localization of NR4A members and inhibits NR4A nuclear export
and cell death. Additionally, NR4A members can either positively regulate oncogenic
signaling pathways (i.e., HIF, β-catenin, mTOR) or overcome tumor suppressor signaling
(i.e., pVHL, p53, LKB1).
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combination with compounds that induce Nur77 nuclear export to yield a higher
apoptotic response.
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CHAPTER 3.

THE ORPHAN NUCLEAR RECEPTOR NR4A2 IS PART OF A
P53–MICRORNA-34 NETWORK
Introduction

The nuclear receptor (NR) superfamily is a group of ligand-regulated transcription
factors that control specific gene activity. NRs are thus important drug targets [9, 15].
The 48 members of the human NR family share a common modular structure that
includes an N-terminal domain containing an activation function 1 (AF-1) region, a
DNA-binding domain (DBD), a hinge region, and a C-terminal ligand-binding domain
(LBD) that also harbors an AF-2 domain. NR subfamily 4 group A (NR4A) consists of
three highly homologous NRs, including NR4A2 (also called Nurr1, NOT, TINUR, or
NGFI-Bβ), that are characterized as immediate-early genes induced by mitogens, growth
factors, and other stimuli [78]. The NR4A receptors have been implicated as having roles
in multiple tissues and diseases, including cancer [86], and their expression and function
are associated with various oncogene and tumor suppressor pathways [45].
NR4A2 is involved in cancer progression through a mechanism that has yet to be
fully described. Most research indicates that NR4A2 has an oncogenic-like role, as it
mediates cell proliferation, survival, transformation, invasion, and migration [88, 90, 92,
118, 209]. NR4A2 is highly expressed in squamous cell carcinoma (SCC), as compared
to normal patient tissues, and prostaglandin-mediated induction of NR4A2 expression in
SCC leads to increased resistance to 5-fluorouracil (5-FU) [93]. The effects of NR4A2 on
chemoresistance are also seen in colorectal cancers [94, 230], and high expression of
NR4A2 predicts a poor outcome for gastric cancer patients receiving 5-FU therapy [231].
NR4A2 may mediate these effects through a previously described NR4A2-p53
interaction that serves to suppress p53 transactivation, thereby protecting cells from p53induced apoptosis [95]. Another NR4A family member, NR4A1 (also called Nur77, TR3,
or NGFI-Bα), has also been implicated in p53 suppression [150].
As the main arbiter of cell cycle progression, DNA repair, and apoptosis, p53 is a
central hub for regulating tumor suppression. These effects are mediated through p53
target genes, which include the microRNA-34 (miR-34) family [70, 71, 75, 232].
MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that help regulate target
gene networks by binding complementarily to the 3′ untranslated regions (UTRs) of
target genes to degrade or prevent their translation into proteins [67]. The miR-34 family,
which consists of three isoforms (miR-34a, miR-34b, and miR-34c) encoded by two p53
direct transcriptional target genes (mir-34a and mir-34b/c), is considered to be partly
responsible for carrying out p53’s tumor suppressive function by targeting the 3′ UTRs of
genes that are critical to the cell cycle and survival, such as BCL2, cyclins, cyclindependent kinases (CDKs), and MYCN [75, 233]. In mice, mir-34a is expressed at higher
levels than mir-34b/c, except in lung tissues, where mir-34b/c is dominantly expressed
[75]. Although miR-34 is dispensable for p53 tumor suppression [234], it is critical for
enhancing p53 stability and activity through miR-34–mediated suppression of negative
regulators of p53, such as Sirt1 [235] and Hdm4 [236]. The miR-34 isoforms have been
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clinically characterized as tumor suppressors in multiple cancer types, often independent
of p53 mutation, as in neuroblastoma, where mir-34a is commonly deleted [73, 74], or in
other cancers characterized by epigenetic silencing of miR-34 [237, 238].
Recently, miR-132 was reported to target mouse Nr4a2 [239, 240]; the first
characterization of an miRNA targeting an NR4A member. In this study, to determine
whether human NR4A2 is regulated by miRNAs and investigate its oncogenic-like role,
we used an miRNA screening approach to identify cancer-relevant posttranscriptional
regulatory networks of NR4A2, a subject that has not been fully explored. We identified
miR-34 as a direct regulator of NR4A2 through a specific sequence in its 3′ UTR.
Furthermore, we determined that elevated miR-34 levels, resulting from exogenous
overexpression or endogenous induction in a p53-dependent manner, decreased the levels
of NR4A2. Corroborating the reported NR4A2-mediated inhibition of p53 [95], we found
that overexpression of NR4A2 inhibited the ability of p53 to activate its target genes,
including mir-34a. Lastly, overexpression of NR4A2 attenuated the sensitivity of cells to
the p53 activator Nutlin-3a. These data are consistent with previous findings and, for the
first time, identify miR-34 as a direct negative regulator of NR4A2. Together, they reveal
a novel regulatory network linking p53, miR-34, and NR4A2, in which p53 can
overcome its inhibition by endogenous NR4A2 through upregulating miR-34.
Results
Identification of miRNAs directly targeting the 3ʹ UTR of NR4A2
Increased NR4A2 expression in cancer has been characterized as resulting from
cell signaling events [45], but miRNA-mediated regulation of NR4A2 in cancer has
hitherto been unexplored. To identify putative miRNAs capable of regulating NR4A2
through its 3′ UTR, we assessed the effects of 75 cancer-relevant miRNAs by using a
luciferase reporter system (Figure 3-1a). Precursor miRNAs selected from an established
library [241] (Table A-1) or an miRNA negative control (pSIF) were cotransfected with
the NR4A2 3′ UTR reporter plasmid (WT 3UTR) in 293T cells. We observed that several
miRNAs, including miR-34c, were capable of decreasing the luminescence reporter
signal to a significantly greater extent than was miR-132, an miRNA that targets Nr4a2
[239, 240] (log2 fold changes of −0.47521 and –0.29685, respectively; P ≤ 0.0001 and
P = 0.0086, respectively) (Figure 3-1b and Table 3-1). This suggested that miR-34c was
a modulator of NR4A2 through its 3′ UTR.
By using three different miRNA prediction algorithm tools (TargetScan [242],
miRanda [243], and PicTar [244]), we identified NR4A2 as a predicted target of the miR34 family (Table 3-1), further suggesting that this family of miRNAs were regulators of
NR4A2. As expected, miR-132 was also predicted to target NR4A2. To corroborate the
findings from “first-generation” prediction tools, we used the CoMeTa interactive
database [245], which integrates thousands of publicly available gene-expression datasets
with the assumption that the predicted targets of an miRNA will be coexpressed with
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Figure 3-1. Screening for miRNAs that directly target the 3′ UTR of NR4A2.
(a) A reporter plasmid containing the 3′ UTR of NR4A2 downstream from a firefly
luciferase (Fluc) gene was used to identify miRNAs that putatively regulate NR4A2,
relative to an internal Renilla luciferase (Rluc) control gene. (b) 293T cells were
transfected with the NR4A2 3′ UTR (WT 3UTR) reporter construct for 24 h. Transfected
cells were reseeded in 96-well plates and reverse transfected with 75 individual cancerrelevant miRNAs. After 48 h of transfection, a Dual-Glo luciferase assay was performed,
the ratio of Fluc/Rluc was calculated, and the log2 fold change was determined for each
miRNA (n = 3), relative to a transfection control (pSIF, n = 9), and presented as a
waterfall plot. The Fluc/Rluc value for pSIF was set as 1. Statistical significance was
calculated using a one-way ANOVA and Dunnett’s test for multiple comparisons
between pSIF and the indicated miRNAs. (c) A schematic of the predicted miR-34 seed
region in the NR4A2 3′ UTR (WT 3UTR). This predicted miR-34 binding site in the
NR4A2 3′ UTR was mutated, and the resulting loss of complementarity is shown (34mut).
(d) WT 3UTR or 34mut reporter constructs were cotransfected with pSIF or the indicated
miR-34 isoforms into HCT116 colorectal carcinoma cells for 72 h, after which a DualGlo luciferase assay was performed. The fold change of the Fluc/Rluc ratio with respect
to pSIF was calculated (the Fluc/Rluc value of pSIF for each reporter transfection group
was set as 1), and the statistical significance of the relation between pSIF and miR-34a or
miR-34c was determined using a two-way ANOVA and Tukey’s test for multiple
comparisons (****, P ≤ 0.0001; n.s., P > 0.05). Statistically significant changes in WT
3UTR and 34mut for each miRNA transfection are indicated by #### (P ≤ 0.0001).
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Table 3-1.

MicroRNAs that putatively regulate NR4A2 through its 3ʹ UTR.

Rank

miRNA ID

1

hsa-miR-335

2

hsa-miR-34c

3

hsa-miR-144

4

hsa-miR-214

5

hsa-miR-191

6

hsa-miR-15a

7

hsa-miR-155

8

hsa-miR-20a

9

hsa-miR-25

17

hsa-miR-132

Log2 fold
change
−0.47549
± 0.0223
−0.4752
± 0.1028
−0.44443
± 0.0696
−0.37908
± 0.0942
−0.37123
± 0.1471
−0.36165
± 0.0343
−0.36052
± 0.0926
−0.35512
± 0.0296
−0.35227
± 0.128
−0.296850
± 0.1684

P-value

TargetScan

miRanda

PicTar

Other predicted
NR4A genes

< 0.0001

No

No

No

NR4A3

< 0.0001

Yes

Yes

Yes

---

< 0.0001

No

No

No

NR4A3

NOTCH1, PTEN, TGFB1

0.0002

No

Yes

Yes

NR4A1

BCL2L2, EZH2, PTEN,
TWIST1

0.0002

No

No

No

---

CDK6, SOX4

0.0004

No

No

No

NR4A1, NR4A3

0.0004

No

No

No

NR4A3

0.0005

Yes

Yes

Yes

NR4A3

0.0006

No

No

No

NR4A3

0.0086

Yes

Yes

Yes

---
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Other targets
BCL2L2, SOX4, RB1,
RUNX2
BCL2, CCND1, CDK4/6,
FRA1, MET, MYC, MYCN,
SIRT1, SNAI1

BCL2, CCND1, CCND2,
CCNE1, CRKL, VEGFA
APC, FOXO3, MLH1,
RUNX2, SMAD1, SMAD2,
SMAD5
CCND1, CDKN1A, E2F1,
HIF1A, KIT, PTEN
BCL2L11, CDH1, EZH2,
MDM2, TP53
CDKN1A, NR4A2, RB1,
SIRT1

each other. The authors noted that targets falling within the top 50th percentile of the
CoMeTa analysis “co-rank” list for putative miRNA targets are highly predictive, based
on previous dataset validation. CoMeTa analysis indicates that NR4A2 falls within the top
40.568 and 39.182 percentiles for miR-34a and miR-34c-5p, respectively. By using the
prediction algorithms, we identified a predicted miRNA recognition element
complementary to the miR-34 seed region in the 3′ UTR of NR4A2 and mutated this
sequence to disrupt the complementarity in order to determine if there was direct
regulation by miR-34 at this specific site (Figure 3-1c). The wild-type 3′ UTR (WT
3UTR) reporter signal was effectively suppressed by cotransfection of miR-34a or miR34c (52% and 62% of the control level, respectively; P ≤ 0.0001 for all) (Figure 3-1d).
The effect of miR-34a or miR-34c, compared to that of the control, was not significant
when the miRNA was cotransfected with the 3′ UTR containing the seed-region mutation
(34mut). Mutation of this predicted seed region was able to rescue the attenuation of the
luminescence signal by miR-34a or miR-34c (Figure 3-1d), increasing the signal from
52% to 99% and from 62% to 111% of the control level, respectively (P ≤ 0.0001 for all).
These data indicate that miR-34 can target NR4A2 at a specific seed complementarity
region within its 3′ UTR. Furthermore, by analyzing a dataset from 97 patient samples
with rectum adenocarcinoma, we found that the expression of NR4A2 and miR-34a was
inversely correlated to a similar extent as other miR-34 targets AXL [246] and SIRT1
[235] (Figures A-1 and A-2). The read counts for miR-34b and miR-34c in this dataset
were very low (data not shown), which is consistent with the known expression patterns
of mir-34b/c primarily in lung tissues[75], making correlation analyses for the mir-34b/c
isoforms not suitable.
miR-34 regulates endogenous NR4A2 levels
We next determined the in vitro effect of miR-34 on endogenous NR4A2 mRNA
and protein levels through the use of miRNA mimics. Mature miR-34a-5p or miR-34c-5p
mimics or a control (CmiR) were overexpressed in HCT116TP53−/− (KO) or HCT116
wild-type (WT) isogenic cell lines to assess the direct effects of forced miRNA
expression on NR4A2. Transfection of mature miR-34 mimics increased the expression of
each miRNA (Figure 3-2a, b). Transfection of miR-34a-5p slightly increased miR-34c5p expression, probably because of specificity differences in the stem loop primers
caused by the approximately 80% sequence homology of the two miR-34 isoforms.
Overexpression of the miR-34a-5p mimic reduced the endogenous NR4A2 expression to
59% and 64% of the control level in KO and WT cells, respectively, by 12 h posttransfection, whereas overexpression of the miR-34c-5p mimic reduced the NR4A2
expression to 71% and 66% of the control level in KO and WT cells, respectively
(Figure 3-2c), and this effect was independent of p53 status. At 24 h post-transfection,
the effect of the miR-34 mimics on NR4A2 levels in HCT116 with wild-type p53 was no
longer obvious, by comparison to the control. Additionally, the transfection of miR-34
mimics led to increased expression of the p53 target gene CDKN1A/p21 (Figure 3-2d),
increased p53 protein expression and acetylation, and subsequent p21 protein levels
(Figure A-3) in wild-type HCT116 cells. The observation that increased levels of miR-34
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Figure 3-2. miRNA-34 downregulates endogenous NR4A2.
Mature miR-34a and miR-34c mimics (10 nM) were transfected into HCT116TP53−/−
(KO) or HCT116 wild-type (WT) cells for 12 or 24 h. Expression of hsa-miR-34a-5p (a),
hsa-miR-34c-5p (b), NR4A2 (c), and CDKN1A (d) was determined using TaqMan qPCR
probes. Mature miRNA expression was normalized to RNU6B, and NR4A2 and CDKN1A
were normalized to GAPDH. The value for the CmiR-transfected KO cells at each time
point was set as 1. The statistical significance of the results of miR-34 transfections,
compared to those of the control, in each cell line for each time point was calculated
using a two-way ANOVA and Dunnett’s test for multiple comparisons.****, P ≤ 0.0001;
*, P ≤ 0.05. (e) Whole-cell lysates (45 μg) from HCT116TP53–/– (KO) and HCT116 wildtype (WT) cells transfected for 48 h with control (CmiR), miR-34a (34a), or miR-34c
(34c) mimics (10 nM) were assessed for expression of NR4A2 and β-actin protein by
performing Western blotting analysis.

38

led to enhanced p53 protein expression and activity probably reflects the known
suppressive function of miR-34 on negative regulators of p53 protein stability
(Figure A-3) [235, 236], though TP53 gene expression (in terms of mRNA levels) was
also slightly increased by the miR-34 mimics (Figure A-3). The slight but significant
increase in TP53 expression induced by the miR-34 mimics is consistent with the
observation that the levels of NR4A2 correlate inversely with that of TP53 gene
expression, as discussed later. After 48 h of miR-34 mimic overexpression in HCT116
cells, the protein levels of NR4A2 (Figure 3-2e) and another miR-34 target, Sirt1
(Figure A-3), were reduced in both KO and WT cells. Additionally, the effect of mature
miR-34 mimics on NR4A2 expression was assessed in another colorectal cancer cell line,
RKO, with similar results observed on CDKN1A and NR4A2 expression (Figure A-4).
These data demonstrate that exogenous overexpression of a mature miR-34 decreases the
levels of endogenous NR4A2 at both mRNA and protein level, regardless of the p53
status. The differential effect of exogenous miR-34 mimic on endogenous NR4A2 may be
attributable to the different levels of endogenous NR4A2 mRNA in TP53+/+ and
TP53−/− cells, although NR4A2 protein expression was substantially decreased in both
TP53-isogenic backgrounds in response to exogenous miR-34 mimic.
p53 activation suppresses endogenous NR4A2 levels
As mir-34a is a direct transcriptional target of p53 [71, 232], we next sought to
determine if NR4A2 expression was regulated by endogenous miR-34a in a p53dependent manner. We treated cells with a chemical activator of p53, Nutlin-3a [247],
and confirmed that the p53 protein level increased after the treatment in cells expressing
wild-type p53 (WT) but not in p53-deficient (KO) cells (Figure 3-3a). As expected, the
expression of transcriptional targets of p53, CDKN1A/p21 and BBC3/Puma, was also
induced in a p53-dependent manner (Figure 3-3a). HCT116CDKN1A−/− and HCT116BBC3−/−
cells were used to demonstrate that Nutlin-3a acts upstream of CDKN1A/p21 and
BBC3/Puma through p53 (Figure 3-3a). We also found increased expression of
CDKN1A/p21 and mir-34a in cells expressing wild-type p53 (Figure 3-3b, c),
accompanied by decreased NR4A2 transcript levels after 48 h of treatment with Nutlin-3a
(Figure 3-3d). The NR4A family, including NR4A2, are immediate-early responsive
genes that are inducible by many external stimuli [78], and at an earlier time point (24 h),
the levels of NR4A2 mRNA were actually increased by Nutlin-3a (Figure 3-3d). In
agreement with mRNA expression, Nutlin-3a treatment for 48 h also caused a decrease in
the NR4A2 protein expression in WT cells, but not in KO cells (Figure 3-3e), further
demonstrating the p53 requirement for Nutlin-3ainduced NR4A2 decrease. In addition
to NR4A2, Nutlin-3a was also capable of decreasing the protein expression of Sirt1
(Figure 3-3e), a known target of miR-34 [235], suggesting that p53 activation can
regulate other downstream factors, possibly through miR-34. We confirmed these results
in other colorectal cell lines (RKO and SW48) that are isogenic for TP53
(Figures A-5 and A-6). These data indicate that p53 activation can induce the expression
of mir-34a, while also decreasing the endogenous levels of NR4A2 and another known
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Figure 3-3. Nutlin-3a activation of p53 decreases endogenous NR4A2.
(a) HCT116 wild-type (WT), HCT116CDKN1A−/− (p21KO), HCT116TP53−/− (p53KO), and
HCT116BBC3−/− (PumaKO) isogenic cell lines were treated for 48 h with 10 μM of
Nutlin-3a or vehicle control (DMSO). Whole-cell lysates (40 μg) were assessed for
expression of p53, p21, Puma, and β-actin by SDS-PAGE gel electrophoresis. (b–d)
HCT116TP53–/– (KO) and HCT116 wild-type (WT) cells were treated with vehicle control
(DMSO) or Nutlin-3a (5 or 10 μM) for 24 or 48 h. Expression of CDKN1A (b), mir-34a
(c), and NR4A2 (d) was determined using TaqMan qPCR probes (normalized to
GAPDH). The value for DMSO-treated KO cells at each time point was set as 1. The
statistical significance of the results obtained with Nutlin-3a treatments, compared to
those obtained with DMSO, in each cell line for each time point was calculated using a
two-way ANOVA and Dunnett’s test for multiple comparisons. ****, P ≤ 0.0001; ***,
P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. (e) Whole-cell lysates (45 μg) from HCT116TP53–/–
(p53KO) and HCT116 wild-type (WT) cells treated for 48 h with DMSO (0 μM) or
Nutlin-3a (5 or 10 μM) were assessed for expression of indicated proteins by performing
Western blotting analysis.
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target of miR-34 (Sirt1). These results are consistent with the observation that the levels
of miR-34 and NR4A2 are inversely correlated.
Overexpression of NR4A2 suppresses p53 activation
It was previously reported that NR4A2 suppressed the transcriptional activity of
p53 in the presence or absence of doxorubicin [95]. We sought to determine the effects of
NR4A2 overexpression on the induction of p53 activation by Nutlin-3a. HCT116 cells
were transduced with lentivirus expressing empty vector control (EV) or 3xFlag-NR4A2,
and overexpression of NR4A2 was confirmed (Figure 3-4a). The EV- or 3xFlag-NR4A2–
transduced cells were treated with Nutlin-3a to determine the effect on p53 downstream
target genes. Upon Nutlin-3a treatment, overexpression of NR4A2 led to a significant
attenuation of the p53-induced expression of the target genes mir-34a and CDKN1A/p21
(Figure 3-4b, c). To assess the effect of NR4A2 on the binding of p53 to target gene
promoters, we performed a chromatin immunoprecipitation (ChIP) assay. As shown in
Figure A-7, NR4A2 did not decrease p53 occupancy at the target gene promoters [248,
249], suggesting that another mechanism is responsible for the inhibitory effect of
NR4A2 on p53. However, HCT116 cells overexpressing NR4A2 had diminished levels
of p53 mRNA and protein (Figure 3-4d, e and Figure A-7). These data demonstrate that
NR4A2 exerts inhibitory effects on the levels of p53 and its transcriptional target genes,
which is consistent with previously reported results [95] and suggests that the attenuation
of p53 mRNA and protein levels, but not of p53 binding to target gene promoters,
probably contributes to such inhibitory effects.
Knockdown of NR4A2 enhances p53 activation
To further confirm the inhibitory effect of NR4A2 on p53 transcriptional activity,
we investigated the effects of reduced endogenous NR4A2 levels on Nutlin-3a–induced
p53 transcriptional target gene expression. HCT116 cells were transfected with
nontargeting control (NT) or siRNA targeting NR4A2 (siNR4A2), and knockdown of
NR4A2 was confirmed (Figure 3-5a). After 48 h of siRNA-mediated knockdown, the
cells were treated with Nutlin-3a for an additional 24 h to determine the effects of NR4A2
knockdown on p53 target gene expression. We found that knocking down NR4A2 caused
an enhancement of Nutlin-3a–induced expression of CDKN1A/p21, MDM2, and mir-34a
(Figure 3-5b–d). Consistent with the inhibitory effect of overexpressed NR4A2 on p53
gene expression (Figure 3-4d), knocking down NR4A2 led to an increase in TP53/p53
gene expression for both the DMSO- and Nutlin-3a–treated groups (Figure 3-5e).
Together, these data further suggest that NR4A2 can suppress p53 transcriptional
activity, at least in part, by inhibiting the expression of p53 itself.
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Figure 3-4. NR4A2 overexpression suppresses p53 activation.
HCT116 cells were transduced for 16 h overnight with lentivirus expressing empty vector
(EV) or 3xFlag-NR4A2 (NR4A2). The cell medium was then changed and the cells
remained in culture for a total of 48 h. The cells were then reseeded and treated with
vehicle (DMSO) or Nutlin-3a (5 or 10 μM) for 24 or 48 h. Expression of NR4A2 (a), mir34a (b), CDKN1A (c), and TP53 (d) was determined using TaqMan qPCR probes
(normalized to GAPDH). The value for DMSO-treated EV at each time point was set as
1. The statistical significance of the difference between the results with EV and NR4A2
for each treatment was determined for each time point by using a two-way ANOVA with
Sidak’s multiple comparisons test. ####, P ≤ 0.0001; ###, P ≤ 0.001; ##, P ≤ 0.01; #,
P ≤ 0.05. (e) Whole-cell lysates from HCT116TP53–/– (KO) and HCT116 wild-type (WT)
cells transduced with lentivirus expressing EV or 3xFlag-NR4A2 (F-NR4A2) were
assessed for expression of Flag (indicating NR4A2), p53, and Gapdh protein by
performing SDS-PAGE gel electrophoresis. Relative p53 expression was determined
using Odyssey Image Studio to calculate the ratio of p53 to Gapdh protein band density
(displayed at the bottom of the gel). The ratio for EV in WT cells was set as 1.0.
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Figure 3-5. Knockdown of NR4A2 enhances p53 activation.
HCT116 cells were transfected for 24 h with nontargeting control (NT) or siRNA
targeting NR4A2 (siNR4A2). The culture medium was then changed, and the cells
remained in culture for a total of 48 h. The cells were then treated with vehicle (DMSO)
or Nutlin-3a (10 μM) for 24 h. Expression of NR4A2 (a), CDKN1A (b), MDM2 (c), mir34a (d), and TP53 (e) was determined using TaqMan qPCR probes (normalized to
GAPDH). The value for DMSO-treated NT was set as 1. The statistical significance of
the results was determined using a two-way ANOVA with Tukey’s multiple comparison
test. The significance of the differences within each transfection group between
transfection groups (####, P ≤ 0.0001; ###, P ≤ 0.001; ##, P ≤ 0.01) is represented.
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Overexpression of NR4A2 attenuates Nutlin-3a sensitivity
We next examined the cellular effects of NR4A2-mediated suppression of p53
after Nutlin-3a treatment. HCT116 cells transduced for 48 h with lentivirus expressing
empty vector control (EV) or 3xFlag-NR4A2 were plated in normal growth medium, and
the cell proliferation was monitored using live-cell imaging. After 14 h, the cell culture
medium was replaced with fresh medium containing vehicle (DMSO) or Nutlin-3a (5 or
10 μM), and the monitoring of cell proliferation continued. In EV-expressing cells, the
inhibitory effect of Nutlin-3a on cell proliferation was substantial (Figure 3-6a). In cells
overexpressing NR4A2, Nutlin-3a–induced inhibition of cell proliferation was attenuated
at both concentrations of Nutlin-3a tested (Figure 3-6b). At the end of the real-time
monitoring period (108 h), the cells were collected and their gene expression was
examined to confirm that NR4A2 expression was increased in cells transduced with
NR4A2-expressing lentivirus (Figure 3-6c). These data indicate that overexpression of
NR4A2 attenuates the inhibitory effect of Nutlin-3a on cell proliferation. Together, our
data are consistent with the known oncogenic role of NR4A2 and, for the first time,
identify miR-34 as a negative regulator of NR4A2 and reveal a novel functional network
linking p53, miR-34, and p53.
Discussion
Over the past decade, it has become increasingly evident that miRNA
dysregulation plays an important role in human disease, including the development,
progression, and therapeutic resistance of cancer. This process can be quite complex, as
overlapping miRNA-mRNA networks can be formed, with a single miRNA having
multiple targets or a single mRNA being a target for multiple miRNAs [250]. Research
on miRNA regulation and the validation of biological targets has continued to increase in
an effort to understand the multiple cellular pathways that are affected by specific
miRNAs, and this area remains of particular interest as additional miRNA-based
therapies are investigated and placed into clinical trials [251, 252].
The NR4A family of orphan nuclear receptors has been studied extensively in
various cancer models, and its regulation and function have been connected to multiple
oncogenic and tumor suppressive pathways [45]. However, the contribution of miRNAs
to the expression of the NR4A family is unclear. In this report, we have presented a novel
p53–miR-34 regulatory mechanism of the orphan nuclear receptor NR4A2, in which
miR-34 directly and negatively regulates NR4A2, which is itself able to repress p53induced gene expression to rescue the inhibition of cell proliferation (Figure 3-7). This is
the first miRNA to be characterized as targeting a member of the human NR4A family
[239, 240].
Based on the known roles of NR4A2 in oncogenic processes within cancer, we
posited that a likely candidate miRNA would be one that harbored tumor-suppressive
functions and was downregulated in cancer, consequently leading to upregulation of
NR4A2. As presented here, we identified and described the direct regulation of NR4A2
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Figure 3-6. Overexpression of NR4A2 attenuates Nutlin-3a sensitivity.
HCT116 cells were transduced for 16 h overnight with lentivirus expressing empty vector
(EV) or 3xFlag-NR4A2 (NR4A2). The cell medium was then changed, and the cells
remained in culture for a total of 48 h. The cells were then reseeded into plates and the
cell confluence was monitored using an IncuCyte ZOOM imaging system. After 14 h, the
cell medium was replaced by medium containing vehicle (DMSO) or Nutlin-3a (5 or 10
μM) (indicated by Tx and arrow). The cell confluence for EV-expressing (a) or NR4A2expressing (b) cells was monitored for a total of 108 h. (c) The cells were then collected
and expression of NR4A2 was determined using TaqMan qPCR probes (normalized to
ACTB). The value for DMSO-treated EV was set as 1.
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Figure 3-7. Graphical summary.
Here, we describe a novel miR-34 regulatory mechanism of NR4A2 that can act
downstream of p53 activation. Additionally, our studies extend the finding that NR4A2
can suppress p53 expression and transcriptional targets, including Nutlin-3a–induced
activation of mir-34a. The p53–miR-34 regulation of NR4A2 may serve as a protective
mechanism to prevent p53 suppression by NR4A2, in addition to suppressing other
tumorigenic properties of NR4A2. The long arrow indicates activation; the blunt arrows
indicate inhibition; the blunt arrow with the dotted line highlights the inhibition of
NR4A2 by miR-34 that indirectly activates p53. As tumors lose expression of mir-34, the
expression and function of NR4A2 may become enhanced, shifting the balance from
tumor suppression to tumor progression.
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by miR-34, a well-described tumor suppressor–like miRNA that targets genes involved in
cancer progression and is increasingly being exploited for its therapeutic advantage [233].
Whereas other putative miRNAs were identified as targeting NR4A2, we focused on the
miR-34 family because of the known role of NR4A members in inhibiting p53 [95, 150]
and the positive regulation of miR-34 by p53 [70], thereby framing our discovery of the
regulation of NR4A2 by miR-34 as a possible feedback mechanism. The miR-34
isoforms, predominantly mir-34a, have tumor suppressor functions in multiple cancer
types, which is sometimes attributed to their p53 status [253, 254], though the
mechanisms of chromosomal deletion or epigenetic silencing are also major contributors
[73, 74, 237, 238], and miR-34 expression is prognostic for patient outcome or relapse
[254-257]. Likewise, several studies have demonstrated the ability of miR-34a restoration
to sensitize cells to chemotherapeutic agents, including erlotinib [258],
Adriamycin/doxorubicin [259], and 5-FU [260]. By using a colorectal cancer cell line
pair that was sensitive or resistant to 5-FU, Akao et al. demonstrated that miR-34a was
significantly downregulated in the resistant cells, and this was accompanied by increased
expression of SIRT1, a target of miR-34. The expression of endogenous miR-34a
remained low in 5-FU–resistant cells treated with 5-FU, and the restoration of miR-34a or
knockdown of SIRT1 in the resistant cells overcame their resistant phenotype. In light of
this observation, it would be interesting to study the relationship of miR-34 and NR4A2
with respect to chemoresistance, as increased NR4A2 expression is correlated with worse
patient outcomes with regard to 5-FU therapy [93, 94, 230, 231].
By using an in vitro luminescence reporter-based screening assay and three
computer-based prediction algorithms [242-245], we identified miR-34c as a putative
regulator of NR4A2 via its 3′ UTR region (Figure 3-1 and Table 3-1). This regulatory
effect was confirmed by using mutagenesis of the predicted miRNA recognition element
that is complementary to the miR-34 seed region. Other miRNAs from this screen have
been evaluated using computer-based and mutagenesis approaches (Table 3-1), and the
functional significance of these miRNA regulators of NR4A2 remains to be elucidated in
future studies. Using publically available data, we found a weak negative (inverse)
correlation of miR-34a with NR4A2 (Figures A-1 and A-2), which was similar to the
correlations of miR-34a with other known miR-34 target genes, such as AXL [246] and
SIRT1 [235], although NOTCH1 [259] did not show a negative correlation as expected.
Interestingly, the patient sample data demonstrated two populations of TP53-expressing
cells, and when we considered only those patient tumor samples with normal levels of
TP53, the correlation became stronger. As we would hypothesize, there was a positive
correlation of NR4A2 with AXL and SIRT1 since these genes share a common miRNA
regulator, miR-34. Consistent with our data in Figures 3-4d and 3-5e, the level of NR4A2
was negatively correlated to that of TP53 (Figure A-2).
The next objective was to determine whether miR-34 could regulate endogenous
NR4A2, at both mRNA and protein levels. Indeed, overexpression of mature miR-34
isoforms reduced the endogenous levels of NR4A2 mRNA and protein in both wild-type
and p53-deficient cells (Figures 3-2 and A-4). This would be expected, as forced
expression of exogenous miR-34 bypasses the requirement for p53. Additionally, miR-34
overexpression enhanced the p53 activity in wild-type cells, probably because of the
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known regulatory effect of miR-34 on negative regulators of p53 (Figures 3-2 and A-3).
This effect is largely the result of increased p53 protein levels rather than substantial
changes in TP53 transcript levels (Figure A-3). The effect of miR-34 on NR4A2 was not
as dramatic in the HCT116 p53 wild-type cells, especially at a later time point (24 h)
(Figure 3-2c), possibly because the lower levels of NR4A2 in these cells no longer
respond to exogenous miR-34 expression after the initial transfection, although reduced
protein expression was observed at 48 h post-transfection (Figure 3-2e). This effect
could also result from the delicate balance of NR4A2 expression being regulated directly
by miR-34 or indirectly through cellular stress. Correspondingly, RKO p53 wild-type
cells had higher levels of endogenous NR4A2 and responded better to miR-34 mimics
than their p53-deficient counterpart (Figure A-4), further supporting the notion that
endogenous levels of NR4A2 affect its response to exogenous miR-34.
To further understand the importance of miR-34 regulation of NR4A2 in the
cellular context, we examined the relationship between endogenous miR-34 and
endogenous NR4A2 by using our isogenic cell line pairs that possess wild-type or deleted
TP53. One interesting observation was that treating HCT116 cells with Nutlin-3a at an
early time point (24 h) led to increased NR4A2 expression, but the opposite effect was
observed at a later time point (48 h) (Figure 3-3d). Consistent with this result, the
NR4A2 protein expression was also reduced after 48 h of Nutlin-3a treatment in WT cells
(Figure 3e). The NR4A family are immediate-early genes that are inducible by many
stimuli, including cell stress and cytotoxic agents [78], whereas Nutlin-3a has a p53independent role and can induce a DNA damage response leading to cell cycle arrest
[261]. One of these properties might account for the earlier induction of NR4A2 by
Nutlin-3a, as the NR4A family mediates DNA double-strand break repair [201]. This
hypothesis could be further tested by using MDM2-deficient cells to determine if these
effects are independent of the primary role of Nutlin-3a in Mdm2 inhibition.
Finally, we investigated the previously reported inhibitory effect of NR4A2 on
p53 activation [95] to determine if this regulation had an effect in the cellular context. We
confirmed that overexpression of exogenous NR4A2 can inhibit p53 induction of target
genes in response to Nutlin-3a treatment (Figure 3-4) and that the opposite effect is seen
when NR4A2 expression is reduced by using siRNA (Figure 3-5). Our data indicate that
this effect might be achieved at least partially through NR4A2 suppression of TP53/p53
gene expression. Further investigation is warranted to determine if this suppression
results from direct or indirect repression of the TP53 promoter. The suppressive effect of
NR4A2 on the expression of p53 and its transcriptional targets was not reflected in
changes in the binding of p53 to its target gene promoters. However, this finding may
reflect the sensitivity of the assay, as even in the presence of NR4A2, enough p53 may be
present to saturate the promoter response elements during Nutlin-3a treatment. It is also
possible that NR4A2 is not inhibitory to p53 binding but is repressive of p53
transactivation at its target gene promoters.
NR4A2 inhibition of the p53 response has previously been investigated only with
respect to the genotoxic agent doxorubicin; here, we have demonstrated a similar effect
using a more targeted p53 activator. When cells overexpressing NR4A2 were subjected to
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prolonged treatment with Nutlin-3a, we observed a substantial rescue of cells from
Nutlin-3a–induced inhibition of proliferation (Figure 3-6), suggesting that the inhibitory
effect of NR4A2 on p53 activation is responsible for phenotypic observations that are
indicative of p53-induced tumor suppression. Interestingly, in cells overexpressing
NR4A2, NR4A2 expression was increased in Nutlin-3a–treated cells after prolonged
treatment (Figure 3-6c). This effect may be attributable to the ability of NR4A2 to repress
the inhibition of cell proliferation, and as the selective pressure of Nutlin-3a is applied to
all the cells, those cells expressing the highest levels of NR4A2 persist in culture.
In summary, our study identified and confirmed a novel regulation of NR4A2 by
miR-34. This regulatory effect is observed in the context of p53 activation, and NR4A2
itself is able to repress the p53 response. These events can be regarded as a positive
feedback loop for p53 (Figure 3-7), much like other miR-34 targets that also suppress
p53 [235, 236]. In tumors expressing wild-type p53, this can serve as a means by which
p53 can release itself from repression by NR4A2, further enhancing the p53 response.
Alternatively, cells that contain p53 mutations or that overexpress NR4A2 through other
means may lack the p53-mediated suppression of NR4A2, allowing NR4A2 to perform
other oncogenic activities through its role as a transcription factor. As tumors lose
expression of mir-34, through promoter methylation or the loss of p53, the expression
and function of NR4A2 may become enhanced, shifting the balance from tumor
suppression to tumor progression (Figure 3-7), though this may not be directly traceable
because of the complexity of miRNA-mRNA regulatory networks.
Materials and Methods
Cell culture
All cell lines were grown in culture at 37ºC in 5% CO2. Human embryonic kidney
293T cells (ATCC, Manassas, VA) were grown according to the manufacturer’s protocol.
Human colorectal carcinoma HCT116 wild-type and TP53−/− isogenic cell lines, which
were derived from an adult male harboring a mutation in codon 13 of the ras protooncogene, were obtained from the Genetic Resources Core Facility at Johns Hopkins
University School of Medicine (Baltimore, MD) and grown in McCoy’s 5A medium
(ATCC) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc.,
Rockford, IL) and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA). RKO
human colon carcinoma (derived from a female harboring mutations in BRAF, NF1 and
PIK3CA) and SW48 human colorectal adenocarcinoma (derived from a female harboring
mutations in CTNNB1, FBXW7 and EGFR) (wild-type and TP53−/−) and HCT116
(CDKN1A−/− and BBC3−/−) isogenic cell line pairs [262-264] were obtained from
Horizon Discovery (Cambridge, UK) and grown according to the manufacturer’s
protocol. Cells collected for RNA and protein extraction were detached with 0.05%
trypsin-EDTA (Life Technologies). For all luminescence-based assays, the cells were
plated using phenol-red–free DMEM or RPMI-1640 medium (Life Technologies).
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3ʹ UTR reporter plasmid and microRNA screen
The NR4A2 3′ UTR was cloned by GeneCopoeia, Inc. (Rockville, MD), directly
downstream from a firefly luciferase (Fluc) gene under the control of an SV40 promoter
in the pEZX-MT01 vector, which also contains a Renilla luciferase (Rluc) gene under the
control of a CMV promoter (as a transfection control). This reporter construct (WT
3UTR) was used to identify miRNAs that regulate Fluc activity through binding to the
NR4A2 3′ UTR and degradation or translational inhibition of fused Fluc mRNA. The
Rluc activity was used to normalize the Fluc. The 293T cells were cotransfected for 48 h
with the 3′ UTR reporter plasmid and 75 cancer-related miRNAs selected from a
previously described library [241] (Table A-1) by using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s protocol. Fugene 6 (Promega, Madison,
WI) was used for transient cotransfection of reporter gene plasmids and miRNAs into
HCT116 cells according to the manufacturer’s instructions. Dual-Glo luciferase assays
(Promega, Madison, WI) were performed to measure and calculate the ratios of firefly
and Renilla luciferase activity. Luciferase activity was measured with an EnVision 2102
Multilabel Plate Reader (Perkin Elmer Inc., Waltham, MA).
miRNA target prediction and mutagenesis
Three miRNA target-prediction algorithms were used to identify putative miRNA
regulators of NR4A2: TargetScanHuman, http://www.targetscan.org [242]; miRanda,
http://www.microrna.org [243]; and PicTar, http://pictar.mdc-berlin.de/ [244]. By using
these algorithms, a putative seed region was determined and mutated using site-directed
mutagenesis (Mutagenex, Inc., Piscataway, NJ). Reporter constructs containing either the
wild-type (WT 3UTR) or mutated (34mut) 3′ UTR were used to demonstrate miR-34
specificity in the NR4A2 3′ UTR.
Molecular cloning
NR4A2 cDNA was cloned into the pEXM12-3xFLAG (N-terminal) vector
(GeneCopoeia, Inc.). We used the primers listed in Table A-2 to amplify 3xFLAGNR4A2 cDNA from pEX-3xFLAG-NR4A2 by PCR then subcloned it into a pSin-EF2IRES-Blast lentiviral expression vector (kindly provided by Dr. Mark E. Hatley). All
DNA constructs were confirmed by Sanger sequencing. Lentiviral expression plasmids
were packaged into viral particles using the psPAX2 packaging (Addgene plasmid #
12260) and pMD2.G envelope (Addgene plasmid # 12259) vectors.
miRNA mimics, RNAi, and chemical treatments
Exogenous expression of mature miRNAs was performed with mirVana mimics
transfected using Lipofectamine RNAiMAX reagent (Life Technologies). All chemical
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treatments were performed in full growth medium containing 0.1% dimethyl sulfoxide
(DMSO; as a negative control) (Thermo Fisher Scientific) or Nutlin-3a (Sigma Aldrich)
as specified by the experimental design. Small interfering RNA (siRNA) was obtained
from Dharmacon (Lafayette, CO) and transfected at a concentration of 20 nM using
Lipofectamine RNAiMAX reagent.
RNA extraction and quantitative real-time PCR
RNA was extracted using Maxwell simplyRNA kits and a Maxwell 16 Instrument
(Promega). For the experiments that used miRNA mimics, the total RNA (including
small RNAs) was extracted from the collected cells using miRNeasy Mini kits (Qiagen)
in accordance with the manufacturer’s instructions. RNA concentrations were measured
using a NanoDrop 8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). All
cDNA used in mRNA and miRNA quantitative real-time PCR (qPCR) analyses was
synthesized from extracted RNA by using the SuperScript VILO cDNA synthesis kit
(Life Technologies) according to the manufacturer’s protocol. The mRNA and miRNA
expression data were generated using Applied Biosystems TaqMan assays (20×) and Fast
Advanced Master Mix (Life Technologies). Thermal cycling for qPCR was performed
with an Applied Biosystems 7900HT Fast Real-Time PCR system (Life Technologies) in
accordance with the TaqMan Fast protocol.
Protein extraction and Western blot analysis
Protein was isolated by incubating cells in Pierce RIPA lysis buffer with added
Halt Protease Inhibitor cocktail (Thermo Fisher Scientific) for 30 min on ice then
sonicating the lysate for 10 s at 50% amplitude to shear the DNA. The protein
concentration was measured using the Pierce BCA Protein Assay (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
Protein lysates were resolved on NuPAGE 4–12% SDS-PAGE gradient gels (Life
Technologies). After electrophoresis was completed, the proteins were transferred from
the gels to nitrocellulose membranes with an iBlot dry transfer system (Life
Technologies). Protein gels used for detection of NR4A2 protein were transferred to
polyvinylidene fluoride (PVDF) membranes using wet transfer for 1 h at 100V constant
voltage. The specific antibodies used were rabbit anti-NR4A2 (Santa Cruz
Biotechnology, sc-5568; M-196) (Figure A-8), mouse anti-p53 (Santa Cruz
Biotechnology, sc-65334; B-P3), rabbit anti-Sirt1 (Santa Cruz Biotechnology, sc-15404;
H-300), goat anti-PUMAα (Santa Cruz Biotechnology, sc-19187; N-19); rabbit
antiacetyl-p53 (Lys382) (Cell Signaling, Danvers, MA, #2525); mouse anti-Gapdh
(Ambion, Life Technologies); mouse anti-p21 (Oncogene Research Products, Boston,
MA, OP64); mouse anti–β-actin (Sigma Aldrich, A5441; clone AC-15); and mouse antiFLAG (Sigma Aldrich, F1804; clone M2). All antibodies were diluted in Odyssey
Blocking Buffer (LI-COR Biotechnology, Lincoln, NE). The secondary antibodies were
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goat anti-rabbit and goat anti-mouse IRDye 800WC or IRDye 680LT (LI-COR). All
Western blot imaging was conducted using a LI-COR Odyssey Infrared Imaging System.
Chromatin immunoprecipitation (ChIP)
HCT116 cells transduced with pSin-EF2-IRES-Blast empty vector (EV) or
3xFlag-NR4A2 lentivirus were grown in flasks and treated with vehicle (DMSO, 0.1%)
or Nutlin-3a (10 μM) for 6 h. The chromatin was then crosslinked with 1% formaldehyde
for 10 min. Cell extracts were digested for 10 min with 50 units of micrococcal nuclease
(New England Biolabs, Ipswich, MA) at 37ºC and further sonicated to yield sheared
DNA fragments with an average length of 200 to 1000 base pairs. The sonicated samples
were centrifuged to pellet the cell debris, and the supernatant was diluted 7-fold with
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM TrisHCl, pH 8.1, 167 mM NaCl, and protease inhibitor cocktail). The samples were
precleared with ChIP-grade Protein G agarose beads (Cell Signaling, #9007) in ChIP
dilution buffer (1:1 ratio). Diluted supernatant (100 μL) was reserved as input (10%) for
each treatment. Chromatin (1 mL) was used for each immunoprecipitation and was
incubated overnight at 4ºC with mouse anti-p53 (Santa Cruz Biotechnology, sc-126; DO1) or control mouse IgG. The antibody-protein-DNA complexes were precipitated by
incubation with Protein G–agarose beads for 2 h at 4ºC. The protein-DNA complexes
were eluted from the beads with elution buffer (1% SDS, 0.1 M NaHCO3). The crosslinks
were reversed, and DNA was eluted from the protein-DNA complexes by adding 200
mM NaCl and incubating at least overnight at 65ºC. DNA was recovered and purified
after protein digestion with Proteinase K at 45ºC for 2 h using the Qiagen DNeasy Blood
& Tissue Kit (Qiagen Cat. No: 69506). Quantitative real-time PCR was performed to
determine the changes in p53 occupancy at various known sites of p53 binding. The
double-negative controls were nonspecific antibody (normal mouse IgG) and primers
coding for regions that do not interact with p53. The thermal cycling conditions were
95ºC for 10 min followed by 45 cycles of 25 s at 95ºC, 30 s at 60ºC, and 30 s at 72ºC.
The primers used are listed in Table A-2.
Cell viability assays
Real-time cell growth in response to the various treatments was measured as the
degree of cell confluence in culture plates and was determined using an IncuCyte ZOOM
live-cell imaging system (Essen BioScience, Ann Arbor, MI). Cell proliferation curves
were plotted using confluence values at specified time points for each treatment.
Analyses of expression data from online databases
The RNASeq and miRNASeq dataset of 164 patients with rectum
adenocarcinoma was acquired from the TGCA Research Network:
http://cancergenome.nih.gov/. After log2 transformation of reported normalized_count
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for mRNA expression and read_per_million_miRNA_mapped for mature miRNA
expression, a subset of 97 samples with data generated from the HiSeq platform (for a
consistent and reliable comparison) was investigated. The correlations between the
expression of miR-34a and NR4A2, as well as other published miR-34 targets—AXL
[246], NOTCH1 [259], and SIRT1 [235]—and TP53 were determined by the regression
analysis using Stata software (College Station, TX).
Statistical analyses
All experiments were performed at least three times, and the independent
replicates are represented as mean ± standard deviation. Data normalization, statistical
tests used, and representations of P-value are indicated for each figure in the
corresponding legend.
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CHAPTER 4. INVESTIGATING THE EXPRESSION AND FUNCTION OF
NR4A NUCLEAR RECEPTORS IN RHABDOMYOSARCOMA
Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children,
affecting 350 children and adolescents per year in the United States [265]. RMS is
thought to be derived from the skeletal muscle lineage and of the four subtypes
characterized, two primarily affect children and adolescents—embryonal RMS (ERMS)
and alveolar RMS (ARMS). ERMS is more common and is less aggressive, with these
patients usually being younger and having a much better prognosis [266]. Highly
aggressive ARMS is typically characterized by a fusion gene of PAX3/7-FOXO1 in 80%
of cases [267], forming a transcription factor capable of driving oncogenic behavior in
ARMS [268]. Additionally, other molecular signaling defects have been attributed to
RMS pathogenesis, including Ras, p53, and Sonic hedgehog (Shh) pathways [269].
The NR4A orphan nuclear receptor (NR) family, particularly NR4A1 (Nur77) and
NR4A2 (Nurr1), has been predominantly studied in adult cancers where higher
expression of both have been observed [86, 270]. Gene knockdown of NR4A1 generally
inhibits cell growth and increases apoptosis [86], explaining its importance in cell
proliferation and survival. NR4A1 expression promotes proliferation in a DNA-binding
and transactivation-dependent manner [271]. Conversely, in hematological malignancies,
NR4A1, along with NR4A3 (Nor-1), is found to be downregulated or silenced in mouse
and clinical samples [46]. In agreement with this, NR4A1 and NR4A3 were found to
regulate the expression of many of the same genes [98], indicating their functional
redundancy.
Less is known about how NR4A2 mediates cancer hallmarks. NR4A2 has been
shown to play a role in anchorage-independent cell growth [88, 89]. Also, there is
evidence that NR4A2 can mediate cell migration [90], and others show that NR4A2 can
mediate cell proliferation and xenograft tumor growth [91, 92]. High expression of
NR4A2 is found in squamous cell carcinoma (SCC) compared to normal tissues from
patients, leading to increased resistance to 5-fluorouracil [93]. This suggests that NR4A2
has pro-survival roles or effects on drug resistance [93, 94]. This could be explained
partly by an interaction with p53, in which NR4A2 inhibits p53 oligomerization to
suppress its transactivation of target gene BAX, thus protecting cells from doxorubicininduced apoptosis [95].
Much of these effects are attributable to the interaction of NR4As with various
oncogene and tumor suppressor pathways, as well as downstream regulation of NR4A
target genes [45]. The implications of NR4A expression and function in pediatric cancers
are not known, although we hypothesize that the NR4A receptors will have similar
functions in rhabdomyosarcoma. In this study, we assessed the expression of NR4A NRs
in normal muscle and rhabdomyosarcoma cell lines. We found that, compared to normal
muscle cells, the NR4A NRs are overexpressed in cell lines of RMS origin. When using
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siRNA to knockdown the expression of the NR4A members, we found that NR4A1 and
NR4A2 were able to affect cancer-like properties. Both NR4A1 and NR4A2 knockdown
caused a decrease in cell proliferation, with NR4A2 having a greater effect. This
observation was also supported by an increase in the percentage of cells in the G1 phase
of the cell cycle. Only NR4A2 had an effect on cell migration, while both NR4A1 and
NR4A2 knockdown decreased colony formation. Lastly, we performed a DNA microarray
to assess the overlapping gene expression profiles among the three NR4A receptors in
RMS. We found that knockdown of NR4A1 and NR4A3 had similar transcriptome
profiles, while NR4A2 knockdown had a unique expression signature. Using this
transcriptome data to further understand the unique and shared target genes of the NR4A
receptors, particularly those regulated by NR4A2 to affect cell migration, will offer new
insights into their roles in cancer and metastasis and the potential for therapeutic
manipulation by small molecules or miRNAs.
Results and Discussion
NR4A nuclear receptors are overexpressed in RMS
As summarized by Mohan et al. [270], the NR4A receptors have been shown to
be highly expressed in many tumor types, mostly those of adult origin, including bladder,
breast, colon, liver, and lung cancers. We first sought to determine the expression of the
NR4A subfamily members in RMS cell lines. When comparing the levels of mRNA
expression, we found that all three NR4As had higher expression in the RMS cell lines
(RD, Rh41, and Rh30) in comparison to normal skeletal muscle cells (Figure 4-1). The
expression of both NR4A1 and NR4A2 are higher in the cell models representative of
ARMS, while NR4A3 was expressed equally among the three cell lines. Considering the
known roles of NR4A1 and NR4A2 in promoting cancer phenotypes, such as
proliferation and migration, it is interesting to note that these two NR4A members were
higher in cell lines of the more aggressive RMS subtype. With the multiple pathways
known to regulate NR4A expression, it is possible that increased activity of these
signaling cascades could be the cause of the NR4A overexpression and this remains to be
determined.
Knockdown of NR4A1 and NR4A2 decreases cell proliferation
We next sought to determine the roles that the overexpressed NR4A receptors
have in the RMS cell proliferation. Using Rh30, an RMS cell line of the ARMS subtype
which had the highest expression of the NR4A receptors, we transfected siRNA to
knockdown the expression of each NR4A receptor (Figure 4-2a). After 48 h of siRNAmediated knockdown, we began monitoring cell proliferation using real-time confluence
measurement. We found that knockdown of NR4A1 or NR4A2 was able to reduce the cell
proliferation, with NR4A2 knockdown having a greater effect (Figure 4-2b). This data
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Figure 4-1. NR4A nuclear receptors are overexpressed in rhabdomyosarcoma cell
lines.
The expression of NR4A1, NR4A2, and NR4A3 was determined using Taqman qPCR
probes. The expression of each gene was normalized to GAPDH as an internal control.
The data is presented as the fold-change over HSkMC cells (as determined by 2−∆∆Ct).
The statistical significance of the results was calculated using a two-way ANOVA and
Dunnett’s test for multiple comparisons. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.
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Figure 4-2. Knockdown of NR4A1 and NR4A2 decreases cell proliferation.
Rh30 cells were transfected for 48 h with 50 nM non-targeting (NT) or siRNA against the
NR4A genes. (a) The knockdown of expression was confirmed using Taqman qPCR
probes. (b) Cells were then plated for real-time confluence determination using an
IncuCyte HD imaging system. Rh30 (c) or RD (d) cells were transfected for 48 h with
NT, siNR4A1, or siNR4A2 (25 nM) and DNA content was determined using propidium
iodide (PI) staining and flow cytometry analysis.
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corresponds with the known oncogenic-like effects that NR4A1 and NR4A2 demonstrate
in adult cancer types [86, 270].
Additionally, we determined the cell cycle profile of Rh30 and another RMS cell
line, RD, following knockdown of NR4A1 or NR4A2. We determined that following
siRNA transfection, the percentage of cells in the G1 phase of the cell cycle was
increased with a corresponding decrease in the S-phase cell population (Figure 4-2c, d),
which is indicative of a decreased proliferative capacity. For the instance of NR4A1, this
is likely explained by the regulation of target genes such as CCND2 (cyclin D2) [16],
which plays a critical role in the transition of cells from the G1 to S phase of the cell
cycle. This is also a possible explanation for NR4A2, as it has been previously suggested
to regulate CCND1 (cyclin D1)-dependent proliferation of lung cancer cells [91].
Knockdown of NR4A2 decreases cell migration
Next, we sought to characterize the effects of NR4A knockdown on cell migration
using several assays. We first used siRNA to knockdown each NR4A member in RD
cells (Figure 4-3a). Following 48 h of siRNA-mediated knockdown, we plated the cells
for a wound healing assay. Using real-time imaging, we monitored the wound for 96 h
total, and found that only knockdown of NR4A2 was able to impair the ability for RD
cells to efficiently reconstitute the wound (Figure 4-3b, c). Additionally, Rh30 cells were
transfected with siRNA for 48 h and cell migration was determined using a Boyden
chamber assay in which we allowed the cells to migrate from a serum-free environment
towards a 10% serum-containing environment. Following 24 h of migration, we
determined that siNR4A2 transfection was also able to attenuate the amount of cell
migration through the membrane, which was quantified using image analysis software
(Figure 4-3d, e). These two assays indicate that NR4A2 is able to mediate the migratory
capacity of RMS cells, which is in agreement with previous published data in bladder
cancer [90]. In terms of cancer progression, this could indicate that NR4A2 is involved in
tumor metastasis in RMS. In contrast, other reports indicate an opposite and repressive
role of NR4A2 on migration and invasion of adenocarcinoma cells [272], as well as lower
expression in breast tissue from patients presenting with lymph node metastases [92].
These differences could be because of specific roles that are tissue-dependent, similar of
that to NR4A1 having opposite roles in solid versus hematologic malignancies.
Knockdown of NR4A1 and NR4A2 decreases colony formation
Using the RD and Rh30 cell lines, we again transfected with siRNA targeting the
NR4A members. After 48 h, we performed a clonogenic assay by sparsely plating a
minimal amount of cells and allowing them to form adherent colonies over the course of
10 days. We found that knockdown of NR4A1 could slightly block the formation of cell
clones in both cell lines, while knockdown of NR4A2 could lead to a much greater
attenuation of clonogenicity (Figure 4-4). This data also agrees with Figure 4-2, in that
NR4A2 knockdown had a greater effect on cell proliferation. This further supports the

58

Figure 4-3. Knockdown of NR4A2 decreases cell migration.
RD cells were transfected for 48 h with 50 nM non-targeting (NT), siNR4A1, or siNR4A2.
(a) The knockdown of NR4A expression was confirmed using Taqman qPCR probes. (b)
RD cells were then plated into 24-well ImageLock plates and allowed to reach
confluence for 24 h. A scratch-wound was then made uniformly in each well and
monitored in real-time using an IncuCyte HD imaging system to determine relative
wound confluence. (c) Representative images from real-time monitoring are shown. (d)
Rh30 cells were transfected with siRNA and we performed a transwell chamber assay
followed by crystal violet staining. (e) Migrated cells from 3 fields of each replicate were
counted using ImageJ software.
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Figure 4-4. Knockdown of NR4A1 and NR4A2 decreases colony formation.
RD or Rh30 cells were transfected for 48 h with indicated siRNA (50 nM). Cells (2×103)
were then plated into 6-well plates in normal growth medium and allowed to grow for a
period of 10 days, with medium changes every 2 days. Colonies were then fixed with
methanol and stained with crystal violet to image colony formation.
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proliferative and pro-survival roles of the NR4A receptors, in particular NR4A2, and also
is supported by the known roles of NR4A2 in transformation [88, 89]. The ability of
NR4A2 to affect anchorage-independent colony formation in RMS remains to be
determined.
NR4A2 knockdown leads to an altered transcriptional profile
It is well described that the pro-oncogenic functions of NR4A1 are carried out
through its target genes, which include CCND2 [16], E2F1 [85], survivin [47], and
TXNDC5 [48], but the contributions of NR4A2 to gene expression regulation in cancer
are not well defined To date, a systematic transcriptome study in cancer has not been
completed for the NR4A family, which could yield insights into shared and unique target
genes of the NR4A family. To understand how the NR4A members, particularly NR4A1
and NR4A2, are affecting the cell proliferation and migration in RMS, we performed a
microarray study in which we used siRNA to knockdown the expression of each NR4A
member in either single, double, or triple knockdown combinations. Following 48 h of
siRNA transfection, we confirmed the specificity and efficiency of the siRNA
combinations (Figure 4-5a). We next performed a microarray study to determine the
gene expression changes occurring under each condition. Principal component analysis
(PCA) of the significantly altered genes indicated that the samples containing knockdown
of NR4A2 clustered together, indicating their similarity of gene expression, while those
containing knockdown of NR4A1 or NR4A3 also clustered together (Figure 4-5b). This
supports the current understanding of the NR4A receptors in that NR4A1 and NR4A3
were previously shown to have redundant roles and regulate up to 97% of the same gene
transcripts [98]. This finding is also interesting in that the NR4A2 knockdown causes a
shift in the gene expression profile of significantly altered genes, some of which may
explain the unique effect that NR4A2 has on cell migration in this study (Figure 4-3).
Also, when clustering the samples by significantly upregulated and downregulated genes,
those samples with NR4A2 knockdown clustered together (Figure 4-5c). Several of the
genes significantly altered by NR4A2 knockdown were involved in cell cycle and
motility, and the direct regulation of these genes remains to be determined. Many of the
genes significantly altered by NR4A2 knockdown were increased in expression, which
could indicate a mechanism of gene suppression by NR4A2.
Conclusions
In this study, we have further described the pro-oncogenic properties of the NR4A
family, particularly NR4A1 and NR4A2. This body of data expands the known roles of
this subfamily of NRs into the field of pediatric oncology, where little is known regarding
the function of NR4A members. Using multiple phenotypic assays, we identified that
NR4A1 and NR4A2 can promote cancer cell properties such as proliferation through cell
cycle regulation, migration, and survival and clonogenecity. Additionally, a systematic
microarray study to identify NR4A regulated genes indicated that the effect of NR4A2
depletion has drastic effects on gene expression, which might explain its unique role as a

62

Figure 4-5. Gene expression following NR4A knockdown.
Rh30 cells were transfected for 48 h with siRNA for each NR4A receptor in single,
double, or triple combinations (25 nM NR4A-specific siRNA, 75 nM total siRNA per
sample). (a) Knockdown efficiency and specificity was determined. The expression of
NR4A1, NR4A2, and NR4A3 was determined using Taqman qPCR probes. The expression
of each gene was normalized to GAPDH as an internal control. The data is presented as
the fold-change over non-targeting siRNA (as determined by 2−∆∆Ct). (b) Principal
component analysis was performed on the genes that were significantly upregulated or
downregulated in any of the siRNA conditions. (c) Fold-change of significantly altered
genes over non-targeting is presented as a heatmap (log2 fold change; red = 2.5, blue =
2.5).
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mediator of cell migration in the RMS cells. It remains to be determined which novel
genes are critical for the effects observed following NR4A knockdown, and if these
effects are through direct regulation of novel target genes at promoter binding sites.
Materials and Methods
Cell culture
All cell lines were grown in culture at 37ºC in 5% CO2. Rh30 and RD
rhabdomyosarcoma cell lines (ATCC, Manassas, VA) were grown according to the
manufacturer’s protocol. Rh41 cells were provided by Dr. Peter Houghton and grown in
RPMI-1640 medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Thermo Fisher Scientific, Rockford, IL). Human skeletal muscle cells
(HSkMC; Cell Applications, Inc., San Diego, CA) were cultured according to
manufacturer’s guidelines. Trypsin (0.05%)-EDTA (Life Technologies) was used to
detach cells during passaging and cell collection for RNA and protein extraction. Cells
were grown in the presence of 1% penicillin-streptomycin (Life Technologies) except
during siRNA transfections.
Transfection of siRNA, RNA extraction, and quantitative real-time PCR
Small interfering RNA (siRNA) was obtained from Dharmacon (Lafayette, CO)
and transfected at indicated concentrations using Lipofectamine RNAiMAX reagent (Life
Technologies). Transfections were performed in the absence of antibiotics, and culture
medium was changed after 16 hours of incubation with lipid-siRNA complexes. Maxwell
simplyRNA kits and the Maxwell 16 Instrument (Promega, Madison, WI) were used to
extract RNA from cell samples. RNA concentration was measured using a NanoDrop
8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized
from 2 μg total RNA using the SuperScript VILO cDNA synthesis kit (Life
Technologies) according to the manufacturer’s protocol.. The mRNA expression was
determined using Taqman gene expression assays and Fast Advanced Master Mix (Life
Technologies). The Applied Biosystems 7900HT Fast Real-Time PCR system (Life
Technologies) was used for qPCR thermal cycling.
Cell proliferation and cell cycle assays
Rh30 cells were transfected with siRNA (50 nM) for 48 h and plated (1×105) into
6-well plates to determine real-time cell proliferation in response to NR4A knockdown.
Cell proliferation was measured as cell confluence in culture plates using an IncuCyte
HD live-cell imaging system (Essen BioScience, Ann Arbor, MI). Cell proliferation
curves were plotted using confluence measurements at specified time points for each
siRNA transfection. Cells transfected with siRNA were also collected after 48 h after
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transfection and DNA content was assessed using propidium iodide (PI) staining. Briefly,
1×106 cells were washed with PBS and resuspended in PI solution (0.05 mg/mL PI, 0.1%
sodium citrate, 0.1% Triton X-100). Samples were then treated with RNAse for 30 min at
room temperature, filtered through 40 μm mesh, and analyzed by flow cytometry.
Cell migration assays
Wound healing assays were performed by plating cells into 24-well ImageLock
plates (Essen BioScience) and allowing them to reach full confluence. A scratch-wound
was made using the Essen BioScience Woundmaker to make a consistent scatch across
the middle of the imaging field. Plates were then monitored in real-time for indicated
time points and the ability of cells to migrate towards the center of the wound was
determined using the Essen Cell Migration software module. Boyden chamber migration
assays were performed by plating 2×104 cells with serum-free medium into transwell
chambers with a pore size of 8 μm (BD Biosciences, San Jose, CA). Chambers were
placed in a 12-well plate with 10% serum-containing medium, and cells were allowed to
migrate towards the serum-containing medium for 24 h. Transwell chambers were then
fixed with methanol (Sigma Aldrich) for 10 min and stained with 0.4% crystal violet for
2 h (Sigma Aldrich) and mounted to a glass slide for light microscopy imaging. Three
fields for each replicate were counted using ImageJ software.
Colony formation assay
A clonogenic assay was used to measure the ability of single cells to grow into
cell colonies. After indicated siRNA transfection, 2×103 cells were plated into 6-well
plates in normal growth medium. Culture medium was replaced every 2 days, and
colonies were allowed to form for a total of 10 days. Colonies were then fixed with
methanol for 10 min and stained with 0.05% crystal violet for 2 h and plates were
scanned.
DNA microarray
Rh30 cells were transfected with 25 nM of NR4A-specific siRNA in single,
double, or triple combinations (75 nM total siRNA) for 48 h, then collected for RNA
extraction. Total RNAs were amplified and labeled by using a One-Color Low Input
Quick Amp Labeling kit (Agilent 5190-2305, Santa Clara, CA), followed by hybridizing
to the SurePrint G3 Human GE 8×60K microarray (Agilent-028004) that contains 42,545
unique probes targeting 27,958 Entrez genes. Microarrays were scanned by using an
Agilent array scanner (G2565CA) at 3 μm resolution. Microarray data were extracted by
Agilent Feature Extraction software (v10.5.1.1) using GE1_107_Sep09 protocol. The
quantile normalization on log transformed background-subtracted signal intensity was
performed among all samples, followed by comparison between sets of replicates from
different experimental groups. The Student’s t-test was used to determine the statistical
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significance of the difference between the paired samples from three replicates of each
experiment. The expression of the gene was considered significantly different if p < 0.05
and expression change is greater than two folds for at least one of the group comparisons.
The data process and PCA analysis were performed using Partek software (St. Louis,
MO). Microarray expression data files were deposited in the Gene Expression Omnibus
(GEO) as series record GSE68458.
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CHAPTER 5.

DISCUSSION

NR4A Regulation by miRNAs in Cancer
Many studies have suggested a pro-oncogenic role for the NR4A NRs and, as
such, high expression of these NRs has been identified in multiple tumor types. The
NR4A members are early induced genes, with increased expression during situations
such as mitogenic stimulation, stress, or cell death [78]. Because of this, the cause for the
overexpression of the NR4A members in cancer has been attributed to oncogenic
signaling pathways [45], mostly those regulated by growth factors. The NR4A members
are intertwined with these pathways and frequently can exert effects onto the signaling
pathways as well, including inhibition of tumor suppressor signaling to further enhance
cell proliferation and survival.
One area in which research is lacking for the NR4A receptors is in miRNA
regulation of these NRs, particularly as it relates to cancer. Our lab recently reported that
NR4A1 is regulated by miR-124 [273], the first characterized miRNA regulator of
NR4A1. Upon observation of decreased miR-124 and increased NR4A1 in
medulloblastoma cells, we found that miR-124 overexpression could regulate NR4A1
directly through its 3ʹ UTR. This was able to cause a decrease in NR4A1 target genes and
subsequent reduction in cell proliferation and spheroid growth of medulloblastoma cells.
miR-124 is also reported to target AR to suppress the proliferation of prostate cancer
[274], and miR-124 can target other pro-oncogenic genes [275, 276]. Another miRNA,
miR-132, has been characterized as a regulator of NR4A2 [239], although this
relationship has not been studied in the context of cancer.
Due to the lack of understanding regarding miRNA regulation of NR4A receptors,
we chose to investigate possible mechanisms in which dysregulation of a miRNA might
lead to upregulation of NR4A2 in cancer. We hypothesized for both NR4A1 and NR4A2,
that putative miRNA regulators of these genes would be characterized as tumorsuppressorlike miRNAs. Tumor suppressorlike miRNAs are those that usually target a
gene that is involved in promoting tumorigenesis, and the loss of this tumorsuppressorlike miRNA leads to an enhancement of oncogene expression. miR-124 and
miR-132 have both been reported to contain hypermethylation in their promoters [277,
278], leading to suppression of these miRNAs in cancer, which could in part explain the
observed upregulation of NR4A1 and NR4A2 in cancers, respectively. This mechanism of
miRNA silencing is one common method in which tumors lose their expression of tumorsuppressorlike miRNAs [72].
Using a 3ʹ UTR reporter assay, we screened a set of miRNAs that have been
reported to be involved in cancer, including both oncomiRs and tumor-suppressorlike
miRNAs. From this screen, our second ranked miRNA hit was miR-34, which is a welldescribed p53-regulated miRNA [70, 71]. Due to its direct transcriptional regulation by
p53, miR-34 is described as a tumor-suppressor-like miRNA, as it targets many genes
involved in cell proliferation, migration and metastasis, and suppression of apoptosis
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[75]. Upon p53 activation, miR-34 expression is increased along with other p53 target
genes [71]. Due to the known involvement of NR4A2 in regulating p53 activity [95], we
decided to further investigate the miR-34NR4A2 relationship to determine if a p53miR-34NR4A2 network existed.
Mutagenesis studies confirmed that miR-34 did indeed regulate NR4A2 through
its 3ʹ UTR. Overexpression of exogenous miR-34 was able to decrease NR4A2 at both
gene and protein levels, confirming the regulation of endogenous NR4A2 expression.
The effects of miR-34 were also confirmed to increase the p53 activity, as indicated by
increased levels of acetylated p53 and target gene p21. This was likely through the
observed downregulation of the deacetylase Sirt1 by miR-34 [235], which is a negative
regulator of p53 activity.
To determine if the regulation of NR4A2 by miR-34 had biological relevance, our
next step was to determine their endogenous relationship. To do so, we used a chemical
activator of p53, Nutlin-3a [247], to induce the endogenous levels of miR-34. To
determine the p53-mediated effect, we incorporated isogenic cell line pairs which either
had wild-type p53 or deletion of p53. Using this method, we found that Nutlin-3a could
suppress NR4A2 expression at the gene and protein levels in cells with wild-type p53,
but not in the absence of p53. Future studies will aim to determine if the Nutlin3ainduced attenuation of NR4A2 expression is solely due to miR-34 following p53
activation and not because of other off-target effects. To do this, we will utilize a miR-34
inhibitor or antagomiR to block the endogenously-induced miR-34 during Nutlin-3a
treatment. Alternatively, we can utilize genetic knockout models [234] or CRISPR-Cas9
genome editing to determine the NR4A2 levels in response to p53 activation in the
absence of miR-34.
In the context of tumorigenesis, we used publically available data to determine if
the miR-34NR4A2 relationship was evident based on expression correlations. While
one might expect correlations to exist between a miRNA and its target genes, this does
not always hold true, as the miRNA-mRNA regulatory networks are quite complex [250].
Also, in CoMeTa analyses [245], NR4A2 did not score as a top hit for miR-34 targets, so
we did not expect a robust negative correlation of miR-34 and NR4A2. Using a rectum
carcinoma data set from The Cancer Genome Atlas (TGCA), we found a weak, inverse
correlation of miR-34 with NR4A2, and this negative correlation was similar to the
correlations found between miR-34 and its other published target genes.
Future studies in the lab will involve investigating other miRNAs of interest from
our initial 3ʹ UTR reporter screen. One miRNA in particular is miR-214, which was also
highly ranked in our list of putative miRNAs. miR-214 has been reported to have varying
roles in cancer depending on tissue type [279]. An area of interest is the regulation of
miR-214 during myogenic differentiation [280, 281]. The dysregulation of muscle
differentiation is believed to be a key mechanism of rhabdomyosarcoma tumor
development and efforts are being put forth to target differentiation as a way to force
cells into a non-proliferative state [282]. As we have also shown through our knockdown
studies of NR4A2, there could be importance in studying the relationship of miR-214 and
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NR4A2 in rhabdomyosarcoma, as miR-214 has been reported to be downregulated in
rhabdomyosarcoma [283]. NR4A1 is also predicted to be a target of miR-214. miR-206,
which is a well-described ‘myo-miR’ [284, 285] is also predicted to target several NR4A
members. Studies are currently underway to understand the implications of the NR4A
family in muscle differentiation and rhabdomyosarcoma development and progression,
and to determine if the dynamics of the miR-206/214NR4A relationships are important
in these processes.
NR4A Function in Cancer
Knockdown and overexpression studies have demonstrated the importance of
NR4A1 and NR4A2 in promoting cell proliferation, transformation, migration, and
survival. This effect has been attributed to NR4A1 regulation of specific target genes [16,
47, 48, 85], and several groups have aimed at targeting NR4A1 with small molecules [4755] to alter the expression of its critical downstream mediators of oncogenesis. The target
genes of NR4A2 in cancer have not been well characterized, but NR4A2 has been
associated with chemoresistance [93, 230, 231], possibly through its inhibition of p53
[95].
NR4A2 and p53 suppression
Corresponding to the previous identification of NR4A2-mediated suppression of
p53 activity in response to doxorubicin [95], we found that NR4A2 could also suppress
Nutlin-3ainduced p53 activity. Overexpression of NR4A2 led to an attenuation of p53
target gene p21, while knockdown of NR4A2 further enhanced the Nutlin-3a effect,
suggesting an overall suppressive function of NR4A2. Using chromatin
immunoprecipitation (ChIP), we were not able to clearly see an effect of p53 recruitment
to target gene promoters in response to NR4A2 overexpression. Since NR4A2 expression
is higher in cancer cells, another strategy that we could take is to perform the ChIP during
knockdown of NR4A2 to determine if this can enhance the p53 association with gene
promoters, either in the absence or presence of Nutlin-3a treatment. We also observed a
reduction in both the p53 gene and protein levels in response to NR4A2 overexpression.
Other mechanistic studies should be performed to clearly determine how NR4A2 is
mediating its suppressive effect on p53 and its subsequent activation.
In terms of biological outcome, we found that overexpression of NR4A2 could
also rescue cells from Nutlin-3ainduced inhibition of cell proliferation. After prolonged
treatment and observation, we determined that overexpression of NR4A2 could suppress
the p53 activity as indicated by reduced p21 and miR-34 expression. This model fits with
the known involvement of NR4A2 with chemoresistance to 5-flurouracil [93, 230, 231],
and more studies should be completed to determine the relationship of NR4A2 and miR34 in cell and mouse models of drug resistance.
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These findings hint to a possible feedback loop involving p53, miR-34, and
NR4A2. Future studies related to this research could be to determine if NR4A2 can
mediate effects in cancer depending on the p53 status. This would determine to what
extent the effects of NR4A2 on chemoresistance, proliferation, and migration are
mediated through p53. Additionally, an examination in patient tumor samples should be
done to determine the correlation of NR4A2 expression as it relates to the p53 status and
miR-34 expression.
NR4A receptors in rhabdomyosarcoma
Using cell models of rhabdomyosarcoma (RMS), we sought to understand the
expression and function of the NR4A receptors. We found that the NR4A receptors
generally had higher expression in the RMS cell lines when compared to normal muscle
cells. Knockdown of NR4A1 and NR4A2 was able to reduce cell proliferation and
clonogenicity of RMS cells, with NR4A2 knockdown having the greater effect.
Additionally, only NR4A2 was able to affect cell migration, which is supported by a
previous finding of NR4A2 involvement in migration of bladder cancer cells [90].
To begin to understand how the NR4A receptors mediate their pro-oncogenic
effects in the RMS cells, we performed a microarray study in which we knocked down
the NR4A receptors in single, double, or triple combinations. Not surprisingly, the cells
containing NR4A1 and NR4A3 knockdown tended to cluster together, while those with
NR4A2 had a distinct gene expression profile. Of the significantly altered genes, many of
those altered by NR4A2 knockdown were increased in expression, suggesting a possible
role of NR4A2 in gene suppression which is reported for other nuclear receptors. A small
cluster of genes were identified to be downregulated specifically by NR4A2 knockdown,
and these genes will be validated for direct promoter regulation by NR4A2 to determine
if they are true target genes.
The potential NR4A2-specific target genes from our microarray screen are of
interest, and determining the importance of these genes as downstream mediators of
NR4A2 activity could explain the role that NR4A2 has on cell migration in our
experiments utilizing RMS, as none of the other NR4A members could affect this
phenotypic response. It will also be critical to determine if NR4A2 can mediate its effects
on proliferation and migration in a DNA-bindingdependent manner, which will require
the use of DNA-binding mutants. This is probable due to fact that the RMS cell lines
used contain mutations of p53 [286], so the effects of NR4A2 in these models is likely
not due to the p53-NR4A2 relationship we have reported. Additionally, determining if
upstream regulation of NR4As by miRNAs affects downstream transcriptional targets
would give insights into coregulated gene expression cascades or networks.
Understanding the effects of NR4A on these downstream mediators, either through
miRNA regulation or small molecule inhibitors, can yield valuable information into
potential uses as biomarkers or new biological targets.
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Table A-1.
miRNA ID
hsa-miR-335
hsa-miR-34c
hsa-miR-144
hsa-miR-214
hsa-miR-191
hsa-miR-15a
hsa-miR-155
hsa-miR-20a
hsa-miR-25
hsa-miR-122
hsa-miR-140
hsa-miR-17
hsa-let-7b
hsa-miR-363
hsa-miR-218
hsa-miR-9
hsa-miR-132
hsa-miR-21
hsa-miR-184
hsa-miR-32
hsa-miR-148a
hsa-miR-10b
hsa-miR-30c
hsa-miR-210
hsa-miR-128b
hsa-miR-92a
hsa-miR-133b
hsa-miR-143
hsa-miR-150
hsa-miR-29a
hsa-miR-222
hsa-miR-98
hsa-miR-18a
hsa-miR-181b
hsa-miR-27a
hsa-miR-301a
hsa-miR-130a
hsa-miR-206
hsa-let-7e
hsa-miR-127
hsa-miR-205
hsa-miR-23b
hsa-miR-19a
hsa-miR-212
hsa-miR-34a
hsa-miR-126
hsa-miR-193b
hsa-miR-16
hsa-miR-100
hsa-miR-135b
hsa-miR-193a

List of miRNAs screened.
mirBase v14.0 Accession #
MIMAT0000765
MIMAT0000686
MIMAT0000436
MIMAT0000271
MIMAT0000440
MIMAT0000068
MIMAT0000646
MIMAT0000075
MIMAT0000081
MIMAT0000421
MIMAT0000431
MIMAT0000070
MIMAT0000063
MIMAT0000707
MIMAT0000275
MIMAT0000441
MIMAT0000426
MIMAT0000076
MIMAT0000454
MIMAT0000090
MIMAT0000243
MIMAT0000254
MIMAT0000244
MIMAT0000267
MIMAT0031095
MIMAT0000092
MIMAT0000770
MIMAT0000435
MIMAT0000451
MIMAT0000086
MIMAT0000279
MIMAT0000096
MIMAT0000072
MIMAT0000257
MIMAT0000084
MIMAT0000688
MIMAT0000425
MIMAT0000462
MIMAT0000066
MIMAT0004604
MIMAT0000266
MIMAT0000418
MIMAT0000073
MIMAT0000269
MIMAT0000255
MIMAT0000445
MIMAT0002819
MIMAT0000069
MIMAT0000098
MIMAT0000758
MIMAT0004614

Log2 fold change
−0.475
−0.475
−0.444
−0.379
−0.371
−0.362
−0.361
−0.355
−0.352
−0.348
−0.333
−0.325
−0.314
−0.303
−0.297
−0.297
−0.297
−0.274
−0.268
−0.266
−0.251
−0.237
−0.228
−0.213
−0.203
−0.199
−0.195
−0.184
−0.173
−0.171
−0.164
−0.161
−0.158
−0.143
−0.139
−0.132
−0.127
−0.126
−0.119
−0.117
−0.114
−0.113
−0.112
−0.106
−0.089
−0.078
−0.072
−0.067
−0.059
−0.059
−0.057
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Std. dev.
0.0223
0.1028
0.0696
0.0942
0.1471
0.0343
0.0926
0.0296
0.128
0.0902
0.015
0.0957
0.0205
0.1958
0.0494
0.0711
0.1684
0.0699
0.0717
0.0533
0.1481
0.0745
0.138
0.0814
0.0917
0.0536
0.1246
0.1607
0.1322
0.1333
0.0358
0.0807
0.046
0.1663
0.1611
0.1036
0.0528
0.1139
0.1312
0.2329
0.113
0.0235
0.1182
0.1397
0.2004
0.1309
0.1828
0.0803
0.0657
0.0515
0.0549

P-value
< 0.0001
< 0.0001
< 0.0001
0.0002
0.0002
0.0004
0.0004
0.0005
0.0006
0.0007
0.0016
0.0024
0.0039
0.0066
0.0085
0.0086
0.0086
0.0224
0.0289
0.0317
0.0553
0.0892
0.1213
0.1895
0.2513
0.2774
0.3096
0.3967
0.5083
0.5269
0.5981
0.6303
0.6677
0.8227
0.8586
0.9086
0.9394
0.9474
0.9705
0.9794
0.9807
0.9812
0.982
0.9843
0.9983
0.9986
0.9988
0.9989
0.999
0.999
0.9991

Significance
****
****
****
***
***
***
***
***
***
***
**
**
**
**
**
**
**
*
*
*
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns

Table A-1.

(Continued).

miRNA ID
hsa-miR-146b
hsa-miR-125a
hsa-miR-181d
hsa-miR-7
hsa-let-7f
hsa-miR-96
hsa-let-7d
hsa-miR-373
hsa-miR-183
hsa-miR-378
hsa-let-7a
hsa-miR-203
hsa-let-7c
hsa-miR-200c
hsa-miR-29b
hsa-miR-10a
hsa-miR-146a
hsa-miR-199a
hsa-miR-181c
hsa-miR-124
hsa-miR-20b
hsa-miR-27b
hsa-miR-148b
hsa-miR-181a

mirBase v14.0 Accession #
MIMAT0002809
MIMAT0000443
MIMAT0002821
MIMAT0000252
MIMAT0000067
MIMAT0000095
MIMAT0000065
MIMAT0000726
MIMAT0000261
MIMAT0000732
MIMAT0000062
MIMAT0000264
MIMAT0000064
MIMAT0000617
MIMAT0000100
MIMAT0000253
MIMAT0000449
MIMAT0000232
MIMAT0000258
MIMAT0000422
MIMAT0001413
MIMAT0000419
MIMAT0000759
MIMAT0000256

Log2 fold change
−0.051
−0.042
−0.035
−0.031
−0.029
−0.024
−0.013
−0.002
0.0092
0.0094
0.0112
0.0438
0.0536
0.0546
0.0596
0.072
0.0773
0.1012
0.167
0.2023
0.2176
0.2827
0.3025
0.3268

Std. dev.
0.1313
0.088
0.1467
0.0815
0.1111
0.1182
0.0577
0.0811
0.1278
0.0893
0.1743
0.1135
0.1421
0.1715
0.0889
0.1945
0.1303
0.0518
0.1058
0.0932
0.0801
0.1402
0.0726
0.0741

P-value
0.9992
0.9994
0.9995
0.9996
0.9996
0.9997
0.9999
> 0.9999
0.9998
0.9998
0.9997
0.9991
0.999
0.999
0.9988
0.9985
0.9983
0.9824
0.4707
0.1954
0.1232
0.0107
0.0043
0.0014

****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, P > 0.05
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Significance
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
*
**
**

Figure A-1. Correlation of miR-34a and NR4A2 expression in rectum
adenocarcinoma patients.
(a) Regression analysis was used to determine the correlation between expression of miR34a and NR4A2 in a subset of 97 patient samples from the TGCA rectum adenocarcinoma
dataset. (b) TP53 expression was determined using HiSeq data from the 97 patient
samples and the distribution of expression is represented. (c) Regression analysis was
used to determine the correlation between expression of mir-34a and NR4A2 in a smaller
subset of 74 patient samples with higher TP53 expression.
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Figure A-2. miR-34a correlation matrix in rectum adenocarcinoma patients.
(a) Expression correlations between miR-34a and indicated genes were determined using
regression analysis in a subset of 97 patient samples from the TGCA rectum
adenocarcinoma dataset. (b) Regression analysis was used to determine the correlation
between expression of miR-34a and indicated genes in a smaller subset of 74 patient
samples with higher TP53 expression.
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Figure A-3. Overexpression of miR-34 increases p53 protein and acetylation
levels.
(a) Control (labeled as CmiR) or miR-34a-5p (34a) or miR-34c-5p (34c) mimics (10 nM)
were transfected into HCT116 isogenic cell lines for 48 h, after which SDS-PAGE gel
electrophoresis and Western blot analysis of the indicated proteins from whole cell
lysates (45 μg) was performed. (b) A schematic of the previously described positivefeedback mechanisms involving p53 and its transcriptionally regulated miRNAs. (c)
Expression of TP53 was determined using a TaqMan qPCR probe after transfection of
control (CmiR), miR-34a-5p, or miR-34c-5p mimics (10 nM) into HCT116 wild-type
(WT) cells for the times indicated. Gene expression was normalized to GAPDH. The
value for the CmiR-transfected WT cells at each time point was set as 1. The statistical
significance of the results for miR-34 transfections, compared to those for the control, at
each time point was calculated using a one-way ANOVA and Dunnett’s test for multiple
comparisons.**, P ≤ 0.01; *, P ≤ 0.05. (d) Whole-cell lysates (45 μg) from HCT116TP53–/–
(TP53–/–) and HCT116 wild-type (TP53+/+) cells transfected for 48 h with CmiR, miR34a-5p (34a), or miR-34c-5p (34c) mimics were assessed for expression of Sirt1 and βactin protein by performing SDS-PAGE gel electrophoresis and Western blot analysis.
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Figure A-4. Overexpression of miR-34 decreases NR4A2 in RKO colorectal cancer
cells.
Mature miR-34a-5p and miR-34c-5p mimics (10 nM) were transfected into RKOTP53–/–
(KO) or RKO wild-type (WT) cells for 12 or 24 h. Expression of hsa-miR-34a-5p (a),
hsa-miR-34c-5p (b), CDKN1A (c), and NR4A2 (d) was determined using TaqMan qPCR
probes. Mature miRNA expression was normalized to RNU48, and CDKN1A and NR4A2
were normalized to GAPDH. The value for the CmiR-transfected KO cells at each time
point was set as 1. The statistical significance of the results for miR-34 transfections for
each cell line, compared to those for the control, at each time point was calculated using a
two-way ANOVA and Dunnett’s test for multiple comparisons. ****, P ≤ 0.0001; ***,
P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.
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Figure A-5. Nutlin-3a enhances p53 and p21 protein levels in RKO and SW48
colorectal cancer cell lines.
RKO (a) and SW48 (b) colorectal cancer cell lines that are isogenic for p53 expression
(TP53−/−, top; TP53+/+, bottom) were treated for the indicated time periods with vehicle
(DMSO) (0 μM) or Nutlin-3a (5 or 10 μM). Whole-cell lysates were assessed for
expression of p53, p21, and Gapdh protein by performing SDS-PAGE gel
electrophoresis.
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Figure A-6. p53 activation by Nutlin-3a decreases NR4A2 in RKO and SW48 cell
lines.
RKOTP53−/− (KO) and RKO wild-type (WT) (a–c) or SW48TP53−/− (KO) and SW48 wildtype (WT) cells (d–f) were treated with vehicle control (DMSO) or Nutlin-3a (5 or 10
μM) for 24 or 48 h. Expression of mir-34a (a, d), CDKN1A (b, e), and NR4A2 (c, f) was
determined using TaqMan qPCR probes (normalized to GAPDH). The value for the
DMSO-treated KO cells at each time point was set as 1. The statistical significance of the
results obtained with Nutlin-3a treatments for each cell line, compared to those obtained
with DMSO, for each time point was calculated using a two-way ANOVA and Dunnett’s
test for multiple comparisons. ****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01.
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Figure A-7. Overexpression of NR4A2 does not affect binding of p53 to target
gene promoters.
HCT116 wild-type cells were transduced with empty vector (EV) or 3xFlag-NR4A2
(NR4A2) lentivirus. After 16 h, the medium was changed and the cells were grown in
culture for a total of 48 h. The cells were then reseeded into 150-mm2 flasks and treated
for 6 h with vehicle (DMSO) or Nutlin-3a (10 μM). The chromatin immunoprecipitation
protocol was performed and the occupancy of p53 at the p53-free (a), CDKN1A −2242
(b), CDKN1A −11708 (c), MDM2 (d), and mir-34a (e) promoter regions is shown
(represented as fold-enrichment over IgG). (f) Nuclear-enriched extracts used as input for
the ChIP were resolved on a 4–12% SDS-PAGE gradient gel and probed with antibodies
against Flag (indicating NR4A2), p53, and Gapdh. The statistical significance of the
results was determined using a two-way ANOVA with Tukey’s multiple comparison test.
The significance of the differences within each transduction group (****, P ≤ 0.0001;
***, P ≤ 0.001) and between transduction groups (n.s., P > 0.05) is represented.
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Table A-2.

List of primers used.

Primer name
SpeI-3xFlag fwd

Sequence (5ʹ to 3ʹ)
ATA CTA GTC CAC
CAT GGA CTA CAA
AGA CC

Type
Cloning

BamHI-Nurr1 rev

ATG GAT CCC TAG
AAA GGT AAA GTG
TCC A

Cloning

EF1a fwd seq

TCA AGC CTC AGA
CAG TGG TTC

Sequencing

pSIN rev seq

CCC TAG ATG CAT
GCG GAT CCT TCG

Sequencing

pEZX-MT01 fwd

GAT CCG CGA GAT
CCT GAT
TTG GCG TTA CTA
TGG GAA CAT
ACT ATA TGC TCA
GCC ATT GTG TCT
GCT
CCC TCA GCA TCA
GTG TTA CCA ACC

Sequencing

pEZX-MT01 rev
CDKN1A −3969 bp
RE fwd (p53-free)
CDKN1A −3969 bp
RE rev (p53-free)
CDKN1A −2242 bp
RE fwd
CDKN1A −2242 bp
RE rev
CDKN1A −11708
bp RE fwd
CDKN1A −11708
bp RE rev
MDM2 p53 RE fwd

CTG TGG CTC TGA
TTG GCT TT
CCC TTC CTC ACC
TGA AAA CA
GAG TGG GTG GCT
CAC TCT TC
CTC GCA TCA GCA
ACT CTG G
GAT TGG GCC GGT
TCA GTG G
MDM2 p53 RE rev CAC AGC TGG GAA
AAT GCA TGG
mir-34a p53 RE fwd ACG CTT GTG TTT
CTC AGT CCG
mir-34a p53 RE rev TGG TCT AGT TCC
CGC CTC CT
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Sequencing
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR
ChIP
qPCR

Use
Subcloned 3xFlagNR4A2 into pSIN
lenti expression
plasmid
Subcloned 3xFlagNR4A2 into pSIN
lenti expression
plasmid
Confirm cloning of
3xFlag-NR4A2 into
pSIN plasmid
Confirm cloning of
3xFlag-NR4A2 into
pSIN plasmid
Confirm seed region
mutation
Confirm seed region
mutation
p53 ChIP of p53-free
region in CDKN1A
promoter247
p53 ChIP of p53-free
region in CDKN1A
promoter247
p53 ChIP of CDKN1A
promoter247
p53 ChIP of CDKN1A
promoter247
p53 ChIP of CDKN1A
promoter247
p53 ChIP of CDKN1A
promoter247
p53 ChIP of MDM2
promoter248
p53 ChIP of MDM2
promoter248
p53 ChIP of mir-34a
promoter71
p53 ChIP of mir-34a
promoter71

Figure A-8. Validation of an anti-NR4A2 antibody.
HCT116TP53−/− cells were transfected with nontargeting siRNA (Non-Targ.) or siNR4A2
(20 nM) in 60mm2 dishes. After 24 h of siRNA transfection, 3xFlag-EGFP (Flag-EGFP)
or 3xFlag-NR4A2 (Flag-NR4A2) were transfected for an additional 48 h. Whole cell
lysates (45 μg) were resolved on a 4–12% SDS-PAGE gradient gel and transferred to
PVDF membrane using wet transfer (100V constant for 1 h). Membranes were probed
with antibodies against Flag (detecting overexpressed NR4A2 or EGFP), NR4A2
(detecting both endogenous NR4A2 and Flag-NR4A2), and β-actin. The levels of
endogenous NR4A2 (detected using anti-NR4A2) and Flag-NR4A2 (detected using
either anti-NR4A2 or anti-Flag) decreased in response to siNR4A2 but not Non-Targ.
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